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Venous thromboembolism (VTE) is a major health problem in Western countries.1 
Reported incidence rates for first VTE vary between 1.4 and 1.9 per 1000 person-years.1–3 
Venous thrombosis usually starts in the calf veins, from where it may extend and cause 
deep vein thrombosis (DVT) and subsequent pulmonary embolism (PE). 
 More than a century ago, Virchow postulated 3 main causes of thrombosis: stasis of 
the blood, changes in the vessel wall and changes in the composition of the blood.4 In 
VTE, alterations in blood flow and composition of the blood are the main determinants 
for clot formation. Important risk factors for VTE are surgery, major trauma, prolonged 
immobilization, pregnancy, puerperium, the use of oral contraceptives or hormone 
replacement therapy, malignancy and older age.5 Furthermore, abnormal pro- and 
anticoagulant factors increase thrombotic risk, i.e. factor V Leiden, prothrombin 
G20210A mutation, deficiency of antithrombin, protein C and S, and elevated levels of 
factor VIII.5
 An episode of VTE can have serious consequences. Fifty percent of the patients with 
DVT develop post-thrombotic syndrome in subsequent years.6,7 The post-thrombotic 
syndrome is characterized by injury to the venous valvular system. This causes venous 
insufficiency accompanied with chronic symptoms including pain, venous dilatation, 
edema, pigmentation, skin changes, and venous ulcers. The post-thrombotic syndrome 
is the major factor impairing quality of life in subjects with previous DVT.7 Subjects with 
VTE are at high risk to develop recurrence, with incidence rates reported as high as 26 to 
95 per 1000 person-years.8–10  In addition, subjects with VTE have a high mortality rate. 
About 6% of the patients die in the first month after their event and this percentage 
increases up to 20% within the first year.1 Although mortality rate decreases with time, 
it remains elevated up to eight years after VTE.11 This higher mortality rate is not only 
explained by the high prevalence of malignancy in subjects with VTE.11 
 Recent findings suggest another important consequence of VTE; subjects with first 
VTE seem to be at increased risk to develop arterial thromboembolism (ATE).12 In the 
past decades, VTE and ATE were seen as two different entities due to their different 
presentations and assumed different pathogenesis. ATE, of which myocardial infarction 
and ischemic stroke are most prevalent, is usually a result of vascular endothelial injury. In 
VTE, changes in stasis and composition of the blood are regarded the main determinants 
for clot formation. Important risk factors for ATE are hypertension, hyperlipidemia, 
diabetes, high body mass index and smoking.13–15 These cardiovascular risk factors lead 
to endothelial injury, which evokes the formation of atherosclerotic plaques. This can 
result in full occlusion of the arteries. Unlike VTE, arterial disease develops gradually and 
at places where shear stress is high. Arterial thrombi are often referred to as white clots 
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as they consist mainly of platelets. In contrast, venous thrombi are referred to as red clots 
as they consist mainly of fibrin and red blood cells. For this reason, antiplatelet therapy is 
preferred in preventing ATE, whereas in VTE anticoagulant therapy is recommended. 
 Presently, ATE is the leading cause of death in most western countries.16 Moreover, 
global cardiovascular deaths are projected to increase from 17.1 million in 2004 to 
23.4 million in 2030.16  The recent finding suggesting an association between VTE and 
ATE, therefore, is important and needs further examination.
 The present thesis focuses on the relationship between VTE and ATE. First, we 
examined whether we could confirm the alleged increased risk of ATE after VTE. Second, 
we aimed to get more insight in the etiology and pathogenesis of the diseases to help 
us understand their association. For this reason, we studied the relationship between 
several established arterial cardiovascular risk factors and VTE risk. In addition, we 
studied the effect of abnormal levels of pro- and anticoagulant factors on the risk of ATE. 
Insulin resistance 
Several risk factors for ATE have been investigated with respect to their relationship with 
VTE but, up till now, only obesity has consistently been shown to be an independent 
risk factor for VTE.17–20 Obesity itself is associated with several risk factors that influence 
the risk of ATE (e.g. systolic blood pressure, total cholesterol, high-density lipoprotein, 
triglycerides and, systemic inflammation).21,22 Insulin resistance has been suggested as 
central factor underlying this multifaceted syndrome.23–25
 Subjects with insulin resistance have a subnormal biological response to insulin 
levels with respect to glucose secretion and uptake. This results in elevated serum 
concentrations of insulin and, in some cases, to hyperglycemia. Insulin resistance is 
associated with endothelial damage26–28 and increased levels of several prothrombotic 
factors (e.g. plasminogen activator inhibitor-1 (PAI-1),29,30 fibrinogen31,32 and von 
Willebrand factor (vWf)29 antigen). This suggests that insulin resistance possibly not only 
influences the risk of ATE but also the risk of VTE.
 The potential association of insulin resistance with VTE has only been investigated 
in one small case-control study.33 This study had the unexpected finding that overweight 
subjects with VTE had lower insulin levels than overweight controls.33 Other studies 
investigated the association of diabetes mellitus, fasting glucose and HbA1c with 
the risk of VTE.34–36 In these studies, the focus was on measures of glycemia rather 
than on measures of insulin resistance. Importantly, insulin resistance only leads to 
hyperglycemia once pancreatic beta-cells start to fail.37 Therefore, the question whether 






Cholesterol and triglycerides, together called lipids, fulfill important roles in cell 
membrane and hormone synthesis, and energy supply. However, abnormal levels will 
enhance atherosclerosis of the arteries, which eventually might lead to ATE.
 Lipids are not soluble in water and therefore need to bind to apolipoproteins to 
be transportable through blood. Apolipoproteins contain phospholipids that enhance 
solubility. When lipids and apolipoprotein bind, they form lipoprotein. The most 
important lipoproteins are High-Density Lipoprotein (HDL) and Low-Density Lipoprotein 
(LDL). HDL extracts cholesterol from the cells and transports it back to the liver, which 
takes care of its excretion. As HDL reduces the levels of cholesterol in the tissues, high 
levels are protective for ATE. All other lipoproteins, of which LDL is most important, are 
atherogenic, meaning that they increase the risk of atherosclerosis and thereby the risk 
of ATE. These atherogenic lipoproteins transport lipids from the liver to the organs. 
 Lipid-lowering drugs are prescribed to reduce the increased risk of ATE due to high 
levels of atherogenic lipoproteins. Recently, the Jupiter trial showed that the use of 
lipid-lowering medicine also decreases the risk of VTE.38 Two prospective, observational 
studies also reported a decreased risk of VTE associated with the use of the lipid-
lowering statins.39,40 Studies on the association between lipid profile and VTE, however, 
are inconsistent. Whereas some studies observe an increased risk of VTE in subjects 
with low HDL or high LDL levels,41,42 others do not observe such an association.18,20,43 
A possible explanation for this inconsistency is that studies on the relationship between 
lipid profile and VTE mainly focused on classical lipoproteins (i.e. total cholesterol (TC), 
LDL, HDL and triglycerides (TG)).18,20,44 However, in ATE, apolipoproteins and their ratios 
are possibly stronger predictors for the risk of ATE than the classical lipoproteins.45–47 This 
may also apply to VTE. Therefore, we examined whether (apo-) lipoproteins and their 
ratios are related to VTE.
Albuminuria
In the kidney, blood is filtered to form urine. The glomerular filtration barrier prevents 
large proteins from leaving the circulatory system. One of these large proteins is albumin. 
Healthy subjects only have small amounts of albumin in their urine. In some subjects, 
however, high levels of urinary albumin are detected. A high level of albuminuria can 
indicate specific renal disease,48–50 but is also seen as sensitive marker for generalized 
endothelial damage51,52 and as such, urinary albumin levels can effectively predict ATE 
risk.49,53–55
 Recently, our group showed that elevated albuminuria can also be used as a risk 
indicator for first VTE.56 Subjects with microalbuminuria (30-300 mg/24h) were at a 
2.3-fold increased risk to develop first VTE compared to subjects with albuminuria of 
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less than 15 mg per 24-hour urine collection, whereas people with macroalbuminuria 
(> 300 mg/24h) had a 3.0-fold increased risk compared to their healthy counterparts. 
 It is well recognized that many factors associated with an increased risk for first 
VTE are not related to a higher risk of recurrence.57 This seemingly paradoxical fact has 
recently been explained as index-event bias.58 The index-event bias explains the paradox 
by multicausalitity of a disease. Subjects who develop VTE, for example, have a certain 
risk profile, in which the presence of multiple risk factors will eventually lead to passing 
the threshold of developing VTE.5 When a certain variable, for example albuminuria, is a 
strong risk factor, other risk factors do not have to be present for VTE to develop. Thus, 
subjects will develop first VTE based on either high levels of albuminuria or because of the 
presence of other risk factors. In this latter group, urinary albumin level is not necessarily 
elevated. For first VTE, patients are compared with the general population. Although 
not elevated in all VTE patients, high urinary albumin levels will be more common in 
patients then in the general population. Hence, albuminuria can distinguish between 
people at high and low risk for first VTE. In recurrent VTE, subjects are compared with 
others at high risk for VTE. This risk is either based on high urinary albumin level or 
on an otherwise high risk profile combined with low albumin levels. In other words, 
both subjects with high and subjects with low urinary albumin levels are at increased 
risk for recurrence. The first because of high urinary albumin levels, the latter because 
of the presence of other risk factors. Therefore, high urinary albumin levels no longer 
distinguish between subjects at high and low risk for recurrence. 
 Whether this index-event bias also applies to urinary albumin levels and the risk 
of recurrent VTE is unknown. This information, however, is important for the clinical 
management of patients with VTE. As mentioned before, subjects with VTE are at high risk 
to develop recurrence.8–10 This risk can be reduced by prolonging anticoagulant therapy, 
but prolonging anticoagulation is accompanied by an increased risk of bleeding.59,60 It is 
important that duration of anticoagulant therapy is balanced against the risk of bleeding. 
Therefore, it should be examined whether it is possible to distinguish between subjects 
at low and high risk for recurrence. For this reason, we studied the influence of increased 
urinary albumin levels on VTE recurrence. 
Factor VIII 
Factor VIII is an essential prothrombotic protein. Elevated levels are related to an 
increased risk of VTE.61,62 Factor VIII level is partly genetically determined63 but is also 
associated with an inflammatory state.64 An inflammatory state probably mediates the 
development of ATE in subjects with arterial thrombotic risk factors.65–69 This suggests 
that elevated factor VIII levels might also be associated with an increased ATE risk. 
Indeed, literature implies such an association.61,70 However, it is unknown whether this 
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association is acquired or genetic. This question was addressed in a large cohort of 
families with thrombophilic defects.  
Protein S
Protein S is a vitamin K-dependent anticoagulant protein. In the circulatory system 
protein S exists both in a free form and bound to protein C4b-binding protein. Only the 
free form is active in the inhibition of thrombus formation. Low levels of free protein S 
are associated with an increased risk of VTE.71 As with Factor VIII level, free protein S 
level is partly genetically influenced72 but is also associated with inflammatory state.73 
Again, as an inflammatory state probably mediates the development of ATE in the 
presence of arterial thrombotic risk factors,65–69 free protein S level might also be a risk 
indicator for ATE risk, next to Factor VIII level. Most studies on free protein S and ATE risk 
are limited to case reports or small case series.74–76 We investigated this issue in a large 
family cohort.
Outline of the thesis
In the present thesis the association between VTE and ATE is studied. First we 
describe whether we could confirm the alleged association between the two diseases 
in the population-based cohort of the PREVEND (Prevention of REnal and Vascular 
ENd-stage Disease) Study (chapter 2). The PREVEND Study is a prospective, observational 
cohort study, originally designed to investigate the natural course of albuminuria and 
its relation with renal and cardiovascular disease (see figure 1).77 The study started in 
1997 by inviting all inhabitants of the city of Groningen, the Netherlands, aged 28 to 
75 years, to participate. Out of 85 421 subjects invited, 40 856 (48%) responded by 
sending a morning urine sample and answering a short questionnaire. The database 
of these 40 856 subjects is linked yearly to the database of the national registry of 
hospital discharge diagnoses (Prismant, Utrecht, the Netherlands) and the national 
mortality registry (Central Bureau of Statistics, The Hague/Heerlen, the Netherlands). 
This provided us with data on ATE. In addition to these databases, the database of the 
regional anticoagulation clinic was used to identify subjects with VTE. With the use of 
this data, we assessed the absolute and relative risks of ATE after prior VTE in order to 
investigate the magnitude of the association between the two diseases (chapter 2). 
 After confirmation of the association between VTE and ATE we tried to find an 
explanation for this association. For this purpose we studied the relationship between 
several established arterial cardiovascular risk factors and VTE risk. In addition, we 
studied the effect of abnormal levels of pro- and anticoagulant factors on the risk of ATE. 
 In chapter 3 and chapter 4 the association between insulin resistance and VTE 
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and the association between lipid profile and VTE are described. To study these issues, 
we used a subset of the 40 856 subjects previously described. This subset forms the 
actual PREVEND cohort and consists of 8592 subjects who are selected to be intensively 
studied and followed over time. The selection is made based on urinary albumin level. 
All subjects with a urinary albumin concentration of 10 mg/l or greater who agreed to 
participate (n = 6000) are selected together with a random sample of 2595 subjects with 
a urinary albumin concentration of less than 10 mg/l. In these 8592 subjects, the relative 
risk of VTE is assessed in relation to different levels of insulin resistance and in relation to 
different levels of several lipid biomarkers.
Figure 1 Flow diagram of the PREVEND Study Cohort
85 421  Invited by mailed questionnaire for spot urine test
40 856  Responded to questionnaire
3395  Randomly selected
8592  Completed baseline screening (1997 - 1998)
2592  Completed the screening protocol 6000  Completed the screening protocol
22 492  Eligible to participate 7768  Eligible to participate
30 890  Had UAC < 10 mg/l 9966  Had UAC ≥ 10 mg/l
8398  Excluded
           7332  Did not consent
             223  Pregnant
             212  Insulin-dependent
             631  Other
2198  Excluded
           1800  Did not consent
               60  Pregnant
            167   Insulin-dependent
            171   Other
44 565  Did not respond
803  Declined to participate 1768  Declined to participate
In chapter 5 the association between urinary albumin level and the risk of recurrent 
VTE is assessed. Out of the baseline PREVEND cohort of 40 856 subjects, 597 developed 
VTE between 1997 and 2009. Those who had a history of VTE and those who were 
using ongoing anticoagulant therapy until the end of the study period are excluded. 
The remaining 351 subjects with first VTE are used to examine whether subjects with 
elevated albumin levels were at increased risk to develop recurrent VTE.
 In chapter 6 the relationship between factor FVIII and free protein S levels and 
ATE incidence is studied. This association is examined in pooled data of four large 
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retrospective family cohort studies.61,78–81 These studies were performed in three 
University Medical Centers in the Netherlands. As no central lab was involved, only 
the data of the University Medical Center of Groningen is used to answer the present 
research question. This way the possibility of interlaboratory variability is excluded. 
The first family cohort study consists of first-degree relatives (i.e., offspring, siblings, 
and/or parents) of consecutive patients (probands) with documented VTE and established 
hereditary deficiencies of either antithrombin, protein C, or protein S. Due to the small 
number of antithrombin deficient probands, second-degree relatives (i.e., grandchildren 
and/or blood related uncles or aunts) with a deficient parent are also identified. Subjects 
were enrolled between April 1999 and July 2004.
 The other three studies consist of first-degree relatives of consecutive patients with 
VTE or premature atherosclerosis (< 50 years of age) and the presence of either the 
prothrombin G20210A mutation, high levels of factor VIII at repeated measurements, 
or hyperhomocysteinemia. Enrollment in these studies started in May 1998 and was 
completed in July 2004. 
 Taken together 1468 relatives are included in the present study (see figure 2). 
Probands are excluded to avoid referral bias. The relatives are tested for deficiencies 
of antithrombin, protein C and protein S, factor V Leiden, prothrombin G20210A, 
and high levels of factor VIII. Physicians at the thrombosis outpatient clinic collected 
detailed information on previous episodes of ATE, risk factors for atherosclerosis, and 
anticoagulant treatment by using a standardized questionnaire and examining medical 
records. This data is used to study the absolute and relative risks for ATE in subjects with 
high levels of factor VIII or low levels of free protein S. 
 In chapter 7 results of previous chapters are summarized. All findings are discussed 
in chapter 8.  
Chapter 1
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Probands (n = 380)
Relatives ≥ 15 yrs total (n = 2451)
Relatives eligible (n = 1933)
Relatives tested (n = 1468)
Relatives analysed for factor VIII (n = 1399)
Relatives analysed for free protein S (n = 1143)
Antithrombin deficiency (n = 12)
Protein C deficiency (n = 40)
Protein S type I deficiency (n = 39)
Protein S type III deficiency (n = 81)
Prothrombin G20210A (n = 40)
High Factor VII (n = 69)
Hyperhomocycteinemia (n = 99)
Deceased (n = 518)
Excluded (n = 465)
Missing data (n = 69)
Missing data (n = 325)
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Large population-based studies are needed to establish the magnitude and duration of 
the recently suggested association between arterial and venous thromboembolism. In 
1997-1998, all inhabitants of Groningen, the Netherlands, aged 28-75 years (n = 85 421), 
were invited to participate in a study that followed and monitored responding subjects 
(n = 40 856) for venous and arterial thromboembolism until 2009. Thromboembolism 
was verified with national registries of hospital discharge diagnoses and death 
certificates, anticoagulation clinic and medical records. During a median follow-up of 
10.7 years, 549 participants developed venous thromboembolism and 3283 developed 
arterial thromboembolism. Annual incidence of arterial thromboembolism after venous 
thromboembolism was 2.03% [95% confidence interval (CI), 1.48-2.71], compared 
to 0.87% (95% CI, 0.84-0.90) in subjects without venous thromboembolism. The 
hazard ratio (HR) of arterial thromboembolism after venous thromboembolism was 
1.40 (95% CI, 1.04-1.88) after adjustment for age, sex and cardiovascular risk factors. 
This risk was highest during the first year after venous thromboembolism [annual 
incidence, 3.00% (95% CI, 1.64-5.04); adjusted HR, 2.01 (95% CI, 1.19-3.40)] and after 
an unprovoked event [annual incidence, 2.53% (95% CI, 1.68-3.66); adjusted HR, 
1.62 (95% CI, 1.11-2.34)]. This study showed that subjects with venous thromboembolism 
are at increased risk for arterial thromboembolism, particularly in the first year after 
venous thromboembolism and after an unprovoked event.
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Introduction
The concept that arterial and venous thromboembolism are separate pathophysiological 
entities has been challenged.1 In 2003, Prandoni et al. were the first to report a twofold 
increased risk for the presence of atherosclerotic plaques in patients with unprovoked 
deep vein thrombosis.2 Since then, several studies have examined the relationship 
between venous thromboembolism and the risk of subsequent arterial thromboembolism 
and confirmed a relationship between the two diseases. However, their generalizability 
is limited due to either a rather small sample-size,3,4 a patient-based cohort3,5 or a lack 
of controls.6 Also, some studies were limited by possible misclassification of outcome 
events due to the retrospective way in which the cardiovascular events were obtained.7,8 
In a recent meta-analysis of Becattini et al.9 no adjustments for age could be made. 
Age is a strong confounder to the risk of both venous and arterial thromboembolism, 
hence, based on this meta-analysis, we can not firmly conclude that the higher incidence 
of arterial thromboembolism after venous thromboembolism is truly related to previous 
venous thrombotic disease, as it can also merely be a result of ageing. The limitations 
of the abovementioned studies preclude an accurate estimation of the absolute 
incidences of cardiovascular arterial disease in patients with venous thromboembolism. 
This information, however, is important for the clinical management of these patients. 
A large population-based study was performed, in which the limitations discussed above 
were taken into account.10 In this study of Sørensen et al., a two- to three-fold increased 
risk of arterial thromboembolism was found after first venous thromboembolism, 
predominantly in the first year following initial venous thromboembolism.10 However, 
large population-based studies on this issue are still needed to further establish the 
magnitude and duration of the association between arterial and venous thrombosis.
 The Prevention of REnal and Vascular ENd stage Disease (PREVEND) Study11 offered 
us the opportunity to investigate the incidence of arterial and venous thrombotic 
disease in a large population-based cohort. We intended to use this study to advance 
our understanding of both arterial and venous thrombotic disease and provide further 
insight into the clinical course of patients with venous thromboembolism. Our aims were 
to establish whether venous thromboembolism is a risk factor for subsequent arterial 
thromboembolism, and to determine the absolute risk of arterial thromboembolism 
after venous thromboembolism, in a prospectively followed population-based cohort of 
more than 40 000 subjects.
 





This study was conducted on participants in the PREVEND Study, which was designed 
to prospectively investigate the natural course of albuminuria and its relationship with 
renal and cardiovascular disease in a large cohort drawn from the general population. 
Within the PREVEND Study design, arterial thromboembolic events were collected 
prospectively.  Details of this study have been published previously11 and can be found 
at http://www.prevend.org. In 1997-1998, all inhabitants of the city of Groningen, 
the Netherlands, aged 28 to 75 years (n = 85 421) were sent a postal questionnaire 
and a vial to collect an early morning urine sample. A total of 40 856 subjects (47.8%) 
responded. Their observation time started at study entry and ended at time of arterial 
thromboembolism, moving out of the city, death or end of study (January 2009). 
 All participants gave written informed consent. The PREVEND Study was approved by 
the local medical ethics committee and was conducted in accordance with the guidelines 
of the Declaration of Helsinki.
Definition of thrombotic events
To identify subjects with arterial and venous thromboembolism, the databases of the 
national registry of hospital discharge diagnoses (Prismant, Utrecht, the Netherlands) 
and death certificates (Central Bureau of Statistics, The Hague/Heerlen, the Netherlands) 
were linked yearly to the PREVEND database. In addition, the database of the regional 
anticoagulation clinic, which monitors the anticoagulant therapy of all inhabitants of the 
city of Groningen, was searched for venous events. When available, data on subjects 
with venous thromboembolism according to any of the abovementioned databases 
was confirmed by patients’ medical records (n = 522). Arterial thromboembolism was 
predefined as acute myocardial infarction [International Classification of Diseases 
(ICD)-code 410], acute and subacute ischemic heart disease (411), occlusion or stenosis 
of the precerebral (433) or cerebral arteries (434), coronary artery bypass grafting 
(CABG) or percutaneous transluminal coronary angioplasty (PTCA), and other vascular 
interventions, such as percutaneous transluminal angioplasty or bypass grafting of aorta 
and peripheral vessels.12
 Deep vein thrombosis had to be confirmed by compression ultrasound, and 
pulmonary embolism by ventilation/perfusion lung scanning, spiral computed 
tomography, or at autopsy. When deep vein thrombosis and pulmonary embolism were 
diagnosed simultaneously, this was classified as pulmonary embolism. Only deep vein 
thrombosis and pulmonary embolism were considered in the present study, other types 
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of venous thrombosis were not included. Venous thromboembolism was classified as 
being provoked when it had occurred at or within three months after exposure to an 
exogenous risk factor including surgery, trauma, immobilization for more than seven 
days, pregnancy, puerperium, the use of oral contraceptives or hormonal replacement 
therapy, or malignancy. Venous thromboembolism was classified as unprovoked when 
no such exogenous risk factor was present.
Measurements
The questionnaire provided information about the presence of established risk factors 
for cardiovascular disease. Subjects were classified as being diabetic when they gave 
a positive answer when questioned if they had been diagnosed with diabetes by a 
physician, regardless of the type of antidiabetic treatment. Subjects were considered 
hypertensive or dyslipidemic when they positively answered the question regarding 
whether high blood pressure or high cholesterol, respectively, had ever been measured. 
Those who reported smoking or having smoked cigarettes during the previous 5 years 
were regarded as smokers. A history of myocardial infarction or stroke was considered 
present if subjects positively answered the question regarding whether they ever 
suffered from myocardial infarction or ischemic stroke.
 Morning urinary albumin concentration was established by a commercial 
immunoturbidimetry assay with sensitivity of 2.3 mg/l and inter- and intra-assay 
coefficients of variation of 2.2 and 2.6%, respectively (BN II, Dade Behring Diagnostica, 
Marburg, Germany).11,13 First morning urine was used for analysis. Albuminuria was 
considered elevated at a concentration of 20 mg/l or more.14
Statistical analysis
We estimated the absolute risk of arterial thromboembolism in subjects with and without 
venous thromboembolism to assess whether venous thromboembolism is a risk factor 
for arterial thromboembolism. The absolute risk was expressed as an annual incidence 
and was calculated by dividing the number of arterial events by the time at risk. The 95% 
confidence intervals (CIs) around the annual incidences were assessed with the Poisson 
distribution assumption. A time-varying exposure Cox proportional hazard model 
was used to estimate whether venous thromboembolism was a risk factor for arterial 
thromboembolism. With this model, we accounted for differences in the onset of venous 
thromboembolism, i.e. subjects were allocated to the non venous thromboembolic 
group and added follow-up time to this group as long as they did not develop venous 
thromboembolism. At the time that subjects developed venous thromboembolism they 
switched to the venous thromboembolic group and started adding follow-up time to 




Baseline characteristics are shown in Table 1. Out of 40 856 participants 46% was 
male. Median follow-up time was 10.7 (IQR, 8.8-11.0) years. Median age at enrollment 
was 60 (IQR, 48-68) and 48 (IQR, 39-60) years for subjects with and without venous 
thromboembolism, respectively. Venous thromboembolism occurred in 549 subjects at 
a median age of 64 years (IQR, 53-73). In 256 subjects the venous event was secondary 
to an external risk factor, 249 events were unprovoked. In 44 events the presence 
or absence of an external risk factor could not be assessed from medical records. 
Arterial thromboembolism occurred in 3283 subjects (ICD-code 410, 33%; 411, 29%; 
433, 5%; 434, 14%; CABG, 8%; PTCA, 5%; other, 6%). Forty-five subjects with venous 
thromboembolism subsequently developed arterial thromboembolism at a median age 
of 72 years (IQR, 65-78). In the group without venous thromboembolism, 3238 subjects 
developed arterial thromboembolism at a median age of 69 years (IQR, 60-74). The type 
of thromboembolic event is shown in Table 2. Type of arterial thromboembolic event 
(ICD-9 coding) was equally distributed between the subjects with and without venous 
thromboembolism (data not shown). 
 In the patients with venous thromboembolism, the median treatment time 
with anticoagulation was 6 (IQR, 3-10) months. Of the 45 subjects who developed 
this group. Adjustments were made for age, sex, hypertension, dyslipidemia, diabetes 
mellitus, smoking status, elevated albuminuria and history of arterial thromboembolism. 
Based on clinically relevant differences, preplanned sensitivity analyses were performed 
for the subgroups of venous thromboembolism (i.e., deep vein thrombosis versus 
pulmonary embolism and unprovoked versus provoked venous thromboembolism). 
Furthermore, a priori planned subanalyses were performed for the first year of follow-
up after venous thromboembolism versus the rest of follow-up, to investigate the 
persistence of venous thromboembolism as a risk factor through time. 
 As hospitalization bias can cause misclassification of outcome events due to 
differences in monitoring subjects with or without venous thromboembolism, an 
additional sensitivity analysis was performed in which only the arterial thromboembolic 
outcome events myocardial infarction, ischemic stroke or death due to arterial 
thromboembolism were regarded. Categorical data are presented as counts and 
percentages, continuous variables as medians with interquartile ranges (IQR).  Statistical 
significance was considered as 2-tailed P < 0.05. Statistical analyses were performed 
using PASW version 18.0 (IBM SPSS, Chicago, IL, USA) and SAS version 9.2 (SAS Institute, 
Inc, Cary, NC, USA). 
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arterial thromboembolism after venous thromboembolism, 17 subjects were still on 
anticoagulant therapy. One subject had stopped taking anticoagulant therapy < 1 month 
before developing arterial thromboembolism, in all others the interval between cessation 
of anticoagulation and arterial thromboembolism was longer than 1 month. 
 In 9547 out of 40 856 participants, follow-up ended prematurely at time of 
non-arterial and non-venous vascular event (n = 220, 0.5%), non-cardiovascular death 
(n = 2222, 5.4%) or moving out of the city (n = 7105, 17.4%). 
VTE = venous thromboembolism. Continuous variables are presented as median (IQR), categorical 
variables as number (%)
TOTAL 549 (100) 40 307 (100)
Male 260 (47) 18 365 (46)
Age at enrollment, y 60 (48-68) 48 (39-60)
Cardiovascular risk factors
Hypertension 197 (36) 11 642 (29)
Dyslipidemia 83 (15) 5566 (14)
Diabetes Mellitus 18 (3) 1033 (3)
Current Smokers 202 (37) 16 946 (42)
Microalbuminuria (≥ 20 mg/l) 60 (11) 3140 (8)
History of arterial thromboembolism 30 (6) 1749 (4)
Table 1 Baseline Characteristics
Subjects with VTE Subjects without VTE
Risk of arterial thromboembolism after venous thromboembolism
Figure 1 shows the risk of arterial thromboembolism after venous thromboembolism. 
The annual incidence of arterial thromboembolism after prior venous thromboembolism 
was 2.03% (95% CI, 1.48-2.71), compared to 0.87% (95% CI, 0.84-0.90) in subjects 
without venous thromboembolism. The crude hazard ratio (HR) of subsequent 
arterial thromboembolism was 2.24 (95% CI, 1.67-3.00; P < 0.001) in subjects with 
venous thromboembolism, compared to subjects without. After adjustment for age, 
sex, cardiovascular risk factors and previous arterial thromboembolism, the HR was 
1.40 (95% CI, 1.04-1.88; P = 0.03). Within this model, age was a strong confounder as 
adjustment for age only resulted in a HR of 1.43 (95% CI, 1.06-1.92; P = 0.02).
 Our preplanned subgroup analysis of venous thromboembolism indicated that 
differences between subjects with deep vein thrombosis and subjects with pulmonary 
embolism were minimal. With an adjusted HR of 1.62 (95% CI, 1.11-2.34; P = 0.01), 
subjects with unprovoked venous thromboembolism were seemingly at higher risk 
of arterial thromboembolism than subjects with provoked venous thromboembolism 
Chapter 2
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[adjusted HR of 1.22 (95% CI, 0.71-2.11; P = 0.47)].
 Risk of arterial thromboembolism was highest within the first year after venous 
thromboembolism with an annual incidence of 3.00% (95% CI, 1.64-5.04) and an 
adjusted HR of 2.01 (95% CI, 1.19-3.40; P = 0.01). This higher risk was predominantly 
found in subjects with deep vein or unprovoked thrombosis [adjusted HR of 2.68 (95% CI, 
1.44-4.99; P = 0.002) and 2.91 (95% CI, 1.57-5.42; P < 0.001), respectively]. After 1 year of 
follow-up, the adjusted HR of arterial thromboembolism after venous thromboembolism 












Acute and subacute ischemic heart disease
Coronary artery bypass grafting
Deep vein thrombosis and pulmonary embolism
Occlusion or stenosis of the precerebral arteries









Table 2 Type of thrombotic event
Number (%)
To explore the influence of misclassification due to hospitalization bias, a subanalysis 
was performed in which cardiovascular outcome was limited to myocardial infarction, 
ischemic stroke and cardiovascular death. Out of the 3283 subjects that developed 
an arterial event during follow-up, 1873 subjects developed myocardial infarction, 
ischemic stroke or cardiovascular death. Twenty-seven of these arterial thromboembolic 
events developed subsequent to venous thromboembolism, while 1846 subjects did 
not suffer from prior venous thromboembolism. The annual incidence of myocardial 
infarction, ischaemic stroke or cardiovascular death in subjects with previous 
venous thromboembolism was 1.22% (95% CI, 0.81-1.77), compared to 0.49% 
(95% CI, 0.47-0.52) in subjects without previous venous thromboembolism. The 
overall crude HR of myocardial infarction, ischemic stroke or cardiovascular death was 
2.34 (95% CI, 1.60-3.42; P < 0.001) in subjects with venous thromboembolism, 
compared to subjects without. Multivariable analysis showed an overall adjusted HR of 
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1.42 (95% CI, 0.97-2.08; P = 0.07). Within the first year, this adjusted HR was 1.93 (95% CI, 
0.96-3.87; P = 0.06).  After 1 year of follow-up, the adjusted HR of myocardial infarction, 
ischemic stroke or cardiovascular death after venous thromboembolism decreased to 1.28 


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































 Arterial and venous thromboembolism
This large population-based cohort study showed that subjects with previous venous 
thromboembolism are at increased risk to develop arterial thromboembolism. 
Although age was a strong confounder to this risk, the risk was still 1.4-fold increased 
after adjustment for age, sex, cardiovascular risk factors and history of arterial 
thromboembolism.
 The overall absolute risk for arterial thromboembolism in subjects with venous 
thromboembolism was as high as 2.0% per year and even 3.0% during the first year 
after a diagnosis of venous thromboembolism. These values approach the absolute 
risk of recurrent venous thromboembolism.15,16 These data indicate that clinicians 
should be aware of the possibility of arterial thromboembolism, as well as recurrent 
venous thromboembolism. It also implicates that the treatment of patients with venous 
thromboembolism may have to be reconsidered. A meta-analysis of Karthikeyan et al.17 
concluded that acetyl salicylic acid, known for its preventive effect for cardiovascular 
disease, is also effective in preventing venous thrombosis. As yet, however, there is 
insufficient evidence to advise a combination of vitamin K antagonists and antiplatelet 
therapy in order to prevent both recurrence and arterial thromboembolism after a 
first venous thromboembolism. Two ongoing studies (Warfasa, agnellig@unipg.it and 
Aspire, aspire@ctc.usyd) address this issue. Another option might be to prescribe 
statins to patients with venous thromboembolism. In addition to their lipid-lowering 
and cardioprotective capacity these drugs also appear to decrease the risk of venous 
thromboembolism.18
 Our results showed that the risk of arterial thromboembolism is highest 
during the first year after venous thromboembolism, especially in patients with 
an unprovoked event. This finding is in accordance with other studies.7,10 The early 
occurrence of cardiovascular events is difficult to understand, as patients with venous 
thromboembolism usually receive anticoagulant therapy in the first3-6 months following 
their event and anticoagulant therapy is known to prevent cardiovascular events.19 In 
the early 1960s it was observed that an increased risk of cardiovascular events occurred 
after cessation of oral anticoagulant therapy.20 This high risk was assigned to a rebound 
effect on coagulant factors.21–23 This notion, however, was not corroborated by others24–26 
and therefore remains controversial. In our cohort, only one subject developed arterial 
thromboembolism within a month after cessation of anticoagulant therapy, indicating 
that the presence of a rebound effect is unlikely. 
 Given these considerations, we hypothesize that the high risk of arterial 
thromboembolism within the first year after venous thromboembolism suggests that 




affecting the venous system might also affect the arterial system. The high risk of arterial 
thromboembolism in subjects with an unprovoked venous event compared to those with 
a provoked event supports this idea, as does our finding that the relationship between 
arterial and venous thromboembolism persists after adjustment for self-reported 
cardiovascular risk factors. Which underlying pathology could relate the two diseases 
cannot be concluded from our study. An explanation could be bodyweight. Obesity 
is related to a higher risk of arterial27,28 and venous thromboembolism.29,30 This might 
partly explain the relationship between arterial and venous thromboembolism through 
endothelial damage and/or the related changes in the levels of procoagulant proteins.31,32 
However, in a subset of patients for whom data on body mass index was available, 
adjustment for body mass index did not affect the risk of arterial thromboembolism 
after venous thromboembolism (data not shown).
 Our study has both strengths and limitations. The strengths include the large 
population-based cohort, long follow-up time, prospectively collected data on arterial 
events, estimation of absolute risks and the adjustments made for age and sex in all 
analyses. A limitation of our study is that the data on cardiovascular risk factors were 
collected using self-reported histories at baseline. Data on the development of arterial 
cardiovascular risk factors during follow-up is not available. Furthermore, data regarding 
anticoagulant therapy were only available for the subjects who developed venous 
thromboembolism during follow-up. Hence, the use of anticoagulants was not included 
in our multivariable analyses and so we were not able to address the recent finding that 
anticoagulation therapy might accelerate arterial calcification.33 The incidence of venous 
thromboembolism in our cohort may be underestimated as venous thromboembolism 
cases were retrospectively identified.  Nonetheless, as compared with other prospective 
studies, our annual incidence of 0.15% is rather high as our cohort was confined to 
individuals younger then 75 years.34 Lastly, the higher risk of arterial thromboembolism 
after venous thromboembolism may be spurious due to misclassification of arterial 
thromboembolism caused by hospitalization bias. Nonetheless, our subanalysis with 
outcome restricted to myocardial infarction, ischemic stroke and death due to arterial 
thrombosis, confirmed the primary analysis. Therefore, we conclude that misclassification 
was only marginal, if present. As shown in Figure 1, subgroup analyses were limited 
due to small numbers of arterial events, resulting in wider confidence intervals. For the 
same reason, we refrained from assessing differences in pulmonary embolism versus 
deep vein thrombosis and unprovoked versus provoked venous thromboembolism in 
this sensitivity analysis with restricted arterial outcome. 
 We conclude from this large cohort study that subjects with venous 
thromboembolism are at an increased risk to develop arterial thromboembolism. This 
risk is especially high in the first year after venous thromboembolism and after an 
unprovoked event. The risk persists after adjustment for age, sex, cardiovascular risk 
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factors and previous arterial thromboembolism. Our findings implicate that the care 
for patients with venous thromboembolism should not only focus on the prevention 
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Background Obesity is an established risk factor for venous thromboembolism (VTE), 
but it is uncertain how this is mediated. Insulin resistance has a central role in the 
pathophysiology of the metabolic effects of obesity. 
Objective We aimed to investigate whether insulin resistance is a risk factor for VTE. 
Methods For this analysis we used the PREVEND prospective community based 
observational cohort study. Insulin resistance was measured as HOMA-IR (homeostasis 
model assessment of insulin resistance) and fasting insulin. VTE was assessed using 
databases of the national registries of hospital discharge diagnoses, death certificates 
and the regional anticoagulation clinic. 
Results Out of 7393 subjects, 114 developed VTE during a median follow-up of 10.5 
years. High HOMA-IR was associated with increased risk of VTE after adjustment for 
traditional cardiovascular risk factors, CRP and markers of endothelial dysfunction 
(hazard ratio [HR], 1.38; 95% confidence interval [95% CI], 1.09-1.75; P = 0.007). When 
body mass index (BMI) was added to the model, BMI was a strong risk predictor for VTE 
(HR, 1.53; 95% CI, 1.24-1.88; P < 0.001) whereas HOMA-IR no longer showed such an 
association (HR, 1.11; 95% CI, 0.85-1.43; P = 0.45). Results were similar for fasting insulin.
Conclusion Our population-based cohort study shows an increased risk of VTE in subjects 
with increasing insulin resistance but not independently of BMI.
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Introduction
Growing evidence shows a relationship between arterial and venous thromboembolism 
(VTE).1 A possible explanation for this relationship is an overlap in risk factors. Several 
cardiovascular risk factors have been investigated regarding their association with VTE.2 
Overweight and obesity appeared to be strongly related to an increased risk of VTE.2–5 
Insulin resistance has a central role in the pathophysiology of the metabolic effects of 
overweight and obesity.6–8 This raises the question whether insulin resistance is also a 
risk factor for VTE. 
 Insulin resistance is associated with endothelial damage9–11 and increased levels 
of several prothrombotic factors (e.g. plasminogen activator inhibitor-1 [PAI-1],12,13 
fibrinogen14,15 and von Willebrand factor [vWf]12 antigen. The potential association of 
insulin resistance with VTE has been investigated in only one relatively small case-control 
study.16 This study had the unexpected finding that overweight subjects with VTE had 
lower insulin levels than overweight controls.16 Therefore, the question of whether 
insulin resistance is a risk factor for venous thromboemoblism in a prospective setting 
remains unanswered to date.  
 The Prevention of REnal and Vascular ENd stage Disease (PREVEND) Study17 is a 
large prospective population-based cohort study in which accurate measurements of 
fasting insulin and the homeostasis model assessment of insulin resistance (HOMA-IR) 
are available for over 7000 subjects. This gave us the opportunity to investigate the 
relationship between insulin resistance and risk of VTE at a population-based level. 
Insulin resistance and venous thromboembolism
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Methods
Study population and design
This study was conducted with participants in the PREVEND Study. Details of this study 
have been published previously.17 In 1997-1998, all inhabitants of the city of Groningen, 
the Netherlands, aged 28-75 years (n = 85 421), were invited to participate in this 
prospective cohort study, aimed at investigating the natural course of albuminuria 
and its relationship with renal and cardiovascular disease. A total of 40 856 subjects 
(47.8%) responded, filled out a questionnaire and had urinary albumin measured. 
Individuals with insulin-dependent diabetes mellitus were excluded from the PREVEND 
Study because the link between cardiovascular or renal disease and microalbuminuria 
in this subpopulation is well established. Pregnant women were excluded from the 
study too, as pregnancy may cause temporary microalbuminuria. All subjects with a 
urinary albumin concentration of 10 mg/l or greater (n = 7768) were invited and 6000 
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agreed to participate. A random control sample of 3394 subjects with a urinary albumin 
concentration of < 10 mg/l was invited and 2592 subjects agreed to participate. These 
8592 subjects completed the screening protocol and form the baseline PREVEND cohort. 
For the present study, subjects with an invalid assessment of insulin resistance were 
excluded: subjects who had not explicitly stated that they had been fasting for at least 
8 h prior to baseline blood sampling (n = 857), subjects who were using oral antidiabetic 
medication (n = 140) and subjects with missing values on glucose or insulin measurement 
at baseline (n = 202). The remaining 7393 subjects were included in the present analysis.
 All participants gave written informed consent. The PREVEND Study was approved by 
the local medical ethics committee and was conducted in accordance with the guidelines 
of the Declaration of Helsinki.
Measurements
Participants visited the outpatient research unit twice for a baseline survey. All 
participants completed a questionnaire, height, weight and waist circumference were 
measured, an 8 h-fasting blood sample was drawn, and two 24-h urine samples were 
collected. Body mass index (BMI) was calculated as weight (kg) divided by square of 
height (m2), and waist/height ratio was calculated as waist circumference (m) divided by 
height (m). During the first and second visit blood pressure was measured, in the supine 
position for 10 minutes with an automatic device (Dinamap XL Model 9300; Johnson-
Johnson Medical, Tempa, USA). Blood pressure values are given as the mean of the last 
two recordings of both visits. High-sensitivity C-reactive protein (hsCRP) and urinary 
albumin concentration were determined by nephelometry (Dade Behring Diagnostic, 
Marburg, Germany). For urinary albumin concentration, the mean of the two 24-h 
samples was used for analysis. Total cholesterol and plasma glucose were measured 
by dry chemistry (Eastman Kodak, Rochester, USA), and triglycerides were measured 
enzymatically. High-density lipoprotein (HDL) was measured using a homogeneous 
method (direct HDL, Aeroset TM System; Abbott Laboratories, Abbott Park, Chicago, IL, 
USA). Plasma antigen level of PAI-1 was measured using an ELISA kit from Technoclone 
(Vienna, Austria). 
Insulin Resistance
As measure for insulin resistance we used both fasting insulin level and HOMA-IR. 
HOMA-IR was calculated as: (glucose [mmol/l] × insulin [μU/ml])/22.5.18 Insulin was 
measured with an AxSym® auto-analyzer (Abbott Diagnostics, Amstelveen, the Netherlands) 
with a threshold of 7 pmol/l and intra-assay and inter-assay coefficients of variation of 
2.6% and 4.3%, respectively. This assay has virtually no cross-reactivity with pro-insulin 
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(0.016% at 106 pg/ml). The correction coefficient applied for calculation of HOMA-IR 
from insulin concentrations is 1 μU/ml = 6.00 pmol/l.19 
Definition of thrombotic events
Subjects with VTE between study entry and 1 January 2009, were identified using 
the database of the regional anticoagulation clinic, which monitors the anticoagulant 
therapy of all inhabitants of the city of Groningen. In addition, the database of the 
national registry of hospital discharge diagnoses (Prismant, Utrecht, the Netherlands) 
was used. To identify fatal cases of VTE, the database of death certificates (Central 
Bureau of Statistics, The Hague/Heerlen, the Netherlands) was searched. When 
available, data on subjects with VTE according to any of the abovementioned databases 
was adjudicated by checking patients’ medical records (n = 110) by an assessor blinded 
for insulin and glucose status of the subject under investigation. Deep vein thrombosis 
had to be confirmed by compression ultrasound, and pulmonary embolism by 
ventilation/perfusion lung scanning, spiral computed tomography, or at autopsy. When 
VTE had occurred at or within 3 months after exposure to an exogenous risk factor, 
including surgery, trauma, immobilization for more than 7 days, pregnancy, puerperium, 
the use of oral contraceptives or hormonal replacement therapy, or malignancy, this 
event was classified as being provoked. VTE was classified as unprovoked when no such 
risk factor was present. 
Statistical analysis
To answer the question of whether insulin resistance increases the risk of VTE we used 
a Cox proportional hazard model. First, univariate analyses were performed for age, sex, 
BMI, insulin resistance, PAI-1 and all cardiovascular risk factors known to be associated 
with insulin resistance (including systolic blood pressure, total cholesterol, HDL, 
triglycerides and hsCRP), and their relationship with VTE. Second, insulin resistance was 
adjusted for age and sex (Model 1). Model 2 included a multivariable analysis, in which 
insulin resistance was additionally adjusted for systolic blood pressure, total cholesterol, 
HDL, triglycerides and hsCRP. In Model 3, additional adjustments were made for 
PAI-1. Finally, BMI was added to this model (Model 4). These analyses were performed 
both with HOMA-IR and fasting insulin as measures for insulin resistance. In these 
analyses several variables were log transformed (loge) to approach a normal distribution 
(i.e. HOMA-IR, fasting insulin, systolic blood pressure, total cholesterol, HDL, triglycerides, 
hsCRP and PAI-1). After transformation these variables were included as continuous 
variables in the Cox proportional hazard model. First order interactions between 
HOMA-IR and the variables included in the models were calculated.
Insulin resistance and venous thromboembolism
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Because the variables under investigation have different units we choose to report 
hazard ratios per standard deviation (SD). Comparing the risk of VTE through increases 
by standard deviation enables good comparison of strength of associations for the 
various parameters under study. The HRs are reported with 95% confidence interval 
(95% CI). Observation time started with study entry and ended at time of VTE, end 
of study (January 2009), death or moving out of the city. Various sub-analyses were 
performed. Firstly, subjects with provoked and unprovoked VTE were analyzed separately. 
Secondly, because insulin resistance is known to be associated with higher urinary 
albumin excretion20,21 and urinary albumin excretion is also related to an increased risk 
of VTE,22 sensitivity analyses were performed with additional adjustments for urinary 
albumin excretion. Thirdly, analyses were repeated with waist/height ratio23 and waist 
circumference24 as measures for body density, because in arterial cardiovascular disease 
these measures are reported to be slightly better in estimating the cardiovascular risk. 
Lastly, designed-based sensitivity analyses were performed, using survey probability 
weights,25 to correct for the enrichment of the cohort for subjects with high levels of 
urinary albumin excretion.
 In the present study, we used a cohort that was originally composed with a different 
aim, namely, to investigate the natural course of albuminuria and its relationship with 
renal and cardiovascular disease. To answer the present research question, we included 
the maximum number of subjects participating in this cohort. Therefore, an a priori 
power and sample size calculation was not performed.
 Correlations were determined between different variables, expressed as Spearman 
non-parametric correlation coefficients. Categorical data are presented as counts and 
percentages. Continuous variables are presented as medians with interquartile ranges 
(IQR) when non-parametric, and as mean with SD when parametric. Statistical difference 
was tested with the Mann-Whitney U-test, Student’s t-test and chi-square test. A 
two-tailed P ≤ 0.05 was considered statistically significant. Statistical analyses were 
performed using PASW version 18.0 (IBM SPSS, Chicago, IL, USA). 
Results
Study population
Baseline characteristics are shown in Table 1. Of the 7393 subjects, 49% were male. Mean 
age at enrollment was 50 (SD, 13) years. In 1841 subjects, follow-up ended prematurely 
at time of death (n = 509, 7%) or moving out of the city (n = 1332, 18%). During a median 
follow-up of 10.5 (IQR, 10.2-10.8) years, 114 subjects developed a VTE at a mean age of 
62 (SD, 13) years. The annual incidence of VTE was 0.16% (95% CI, 0.13-0.19). Deep vein 
thrombosis occurred in 69 subjects, 33 subjects developed pulmonary embolism, and 
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12 subjects developed both deep vein thrombosis and pulmonary embolism. Thrombosis 
at atypical sites did not occur. In 64 subjects VTE was secondary to an external risk 
factor, and 46 events were unprovoked. In four events the presence or absence of an 
external risk factor could not be assessed from medical records. Median glucose level 
was 4.7 (IQR, 4.4-5.1) mmol/l, median insulin level was 7.8 (IQR, 5.5-11.7) μU/ml and 
median HOMA-IR was 1.6 (IQR, 1.1-2.6). Compared to subjects without VTE, subjects 
who developed VTE had significantly higher age, HOMA-IR, systolic blood pressure, BMI, 
waist circumference, waist/height ratio, urinary albumin excretion and levels of glucose, 
insulin, total cholesterol, triglycerides, hsCRP and PAI-1.
 
Risk of VTE according to insulin resistance
A test for interaction of each risk factor with time showed that the proportional 
hazards assumption was not violated. Furthermore, there were no significant first order 
interactions between HOMA-IR and the variables included in the models. Table 2 shows 
VTE = venous thromboembolism, HOMA-IR = homeostasis model assessment of insulin resistance, 
HDL = high-density lipoprotein, hsCRP = high-sensitivity C-reactive protein, PAI-1 = plasminogen 
activator inhibitor-1 antigen, BMI = body mass index, UAE = urinary albumin excretion. Categorical 
data are presented as number (%), continuous variables are presented as medians (IQR) when 


































Age at enrollment, y
hsCRP, mg/l






























the results of the univariate and multivariable analyses of HOMA-IR in relation to overall 
VTE. In the univariate model, increasing HOMA-IR, age, systolic blood pressure, total 
cholesterol, triglycerides, hsCRP, PAI-1 and BMI all significantly increased the risk of 
overall VTE. In Model 2, HOMA-IR was the only cardiovascular risk factor that significantly 
increased the risk of VTE, besides age and hsCRP (HR, 1.45; 95% CI, 1.16-1.81; P = 0.001). 
PAI-1 showed a significant correlation with HOMA-IR (ρ = 0.46, P < 0.001). When PAI-1 
was added to the model (Model 3), HOMA-IR still significantly increased the risk of VTE 
(HR 1.38; 95% CI, 1.09-1.75; P = 0.007). BMI was also strongly associated with HOMA-IR 
(ρ = 0.59, P < 0.001) and when added to the model, BMI appeared to be a strong risk 
predictor for VTE (HR, 1.53; 95% CI, 1.24-1.88; P < 0.001) whereas insulin resistance no 
longer showed such an association (HR, 1.11; 95% CI, 0.85-1.43; P = 0.45).
 Similar results were found when the analyses were repeated with fasting insulin 
as measure for insulin resistance (see Figure 1). In Model 1, fasting insulin increased 
the risk of VTE with an HR of 1.47 (95% CI, 1.22-1.76); P<0.001. In the multivariable 
Model 2 this HR was 1.55 (95% CI, 1.24-1.93; P < 0.001). Further adjustment for PAI-1 
showed an HR of 1.50 (95% CI, 1.19-1.90; P = 0.001). When BMI was added to this model, 
fasting insulin no longer increased the risk of VTE (HR 1.22; 95% CI, 0.94-1.57; P = 0.14).
 When analyses were confined to unprovoked VTE, we found that 
HOMA-IR increased the risk after adjustment for age, sex, systolic blood pressure, 
HDL and total cholesterol, triglycerides, hsCRP and PAI-1 (HR, 1.64; 95% CI, 1.13-2.36; 
P = 0.009). After additional adjustment for BMI this HR decreased to a non-significant 
1.25 (95% CI, 0.83-1.88; P = 0.28). When restricted to provoked VTE, the multivariate 
Model 3 showed an HR of 1.20 (95% CI, 0.87-1.64; P = 0.26). This HR decreased after 
additional adjustment for BMI to 1.03 (95% CI, 0.73-1.45; P = 0.86).
 When analyses were repeated with additional adjustments for urinary albumin 
level, similar results were found: the HR of HOMA-IR for overall VTE was 1.36 (95% CI, 
1.07-1.72; P = 0.01) in Model 3. After additional adjustment for BMI, this HR was 1.09 
(95% CI, 0.84-1.41; P = 0.51), in Model 4.
 Sensitivity analyses were performed in which waist circumference and 
waist/height ratio were used instead of BMI. Both variables were strong univariate 
risk factors for overall VTE (HR, 1.85; 95% CI, 1.57-2.19; P < 0.001 and 1.84; 95% CI, 
1.57-2.15; P < 0.001 for waist circumference and waist/height ratio, respectively). 
Waist circumference (ρ = 0.56, P < 0.001) and waist/height ratio (ρ = 0.59, P < 0.001) 
showed strong correlations with HOMA-IR and when added to the multivariable 
Model 3, waist circumference (HR, 1.55 [95% CI, 1.20-1.99], P = 0.001) and 
waist/height ratio (HR, 1.48; 95% CI, 1.16-1.89; P = 0.002) remained significantly 
associated with an increased risk of overall VTE, while HOMA-IR was no longer a risk factor 
(HR, 1.14; 95% CI, 0.89-1.48; P = 0.30 and 1.16; 95% CI, 0.90-1.49; P = 0.25 for waist 
circumference and waist/height ratio, respectively).
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When the models were adjusted for the enrichment of the study cohort with participants 
with higher urinary albumin levels, using survey probability weights,25 the corresponding 
HRs were 1.75 (95% CI, 1.26-2.42; P = 0.001) in Model 3 and 1.29 (95% CI, 0.93-1.79; 
P = 0.13) in Model 4, in which BMI was added to the multivariable analysis. 
































































HOMA-IR = homeostasis model assessment of insulin resistance
Model 1: multivariable model including: HOMA-IR, age and sex; Model 2: as model 1 with additional 
adjustment for systolic blood pressure, total cholesterol, high-density lipoprotein, triglycerides 
and high-sensitivity C-reactive protein; Model 3: as model 2 with additional adjustment for PAI-1; 
Model 4: as model 3 with additional adjustment for body mass index
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Discussion
The present study is the first population-based study investigating the relationship 
between insulin resistance and risk of VTE. Subjects with higher levels of insulin resistance 
had an increased risk of VTE, mainly driven by an increased risk of unprovoked events. The 
higher risk in subjects with higher levels of insulin resistance was independent of several 
risk factors related to insulin resistance, including age, sex, systolic blood pressure, HDL 
and total cholesterol, triglycerides, hsCRP and urinary albumin level. However, BMI and 
insulin resistance were strongly related and insulin resistance was not an independent 
risk factor for VTE when BMI was added to the model. BMI itself strongly increased the 
risk of VTE. 
 Only one relatively small case-control study reported on the relationship between 
insulin levels and VTE.16 This study compared insulin levels between subjects with and 
without VTE. In normal weight subjects no difference in insulin level between patients 
and controls was found. In overweight subjects, the authors had the unexpected finding 
that patients had significantly lower levels of insulin when compared with controls.16 
Our study does not show such a relationship. A reason for this discrepancy could be the 
fact that multiple testing in small groups was performed in the case-control study, which 
may have caused chance findings. Aside from this case-control study, no other studies 
have previously investigated the relationship between insulin resistance and VTE. Two 
cohort studies investigated the relationship between glucose levels or HbA1c and VTE 
in subjects with the metabolic syndrome.26,27 In accordance with our results, these 
studies show that BMI was the main determinant of the metabolic syndrome that was 
associated with the increased risk of VTE.26,27 Unlike the present study, these studies did 
not examine insulin resistance, but beta-cell insufficiency and VTE. Importantly, insulin 
resistance only leads to hyperglycemia once pancreatic beta-cells start to fail.28  
 When studying insulin resistance, we also found that none of the cardiovascular 
or procoagulant risk factors independently increased the risk of VTE, except for BMI. A 
possible explanation for this finding could be the strong relationship between insulin 
resistance and BMI. Like insulin resistance, BMI itself is also related to endothelial 
damage and increased levels of several prothrombotic risk factors.29–31 It is possible that 
the studies that showed a relationship between insulin resistance and prothrombotic 
state were actually looking at the relationship between BMI and prothrombotic state. 
However, the few studies that did adjust for BMI still found an independent relationship 
between insulin resistance and prothrombotic state.12,29 It may well be that these 
prothrombotic changes are not severe enough to cause thrombosis or are counteracted 
by an increase in levels of anticoagulant factors. Our results thus suggest that insulin 
resistance is not the main pathway for the development of VTE in overweight or obese 
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subjects. Indeed, high levels of BMI can influence thrombotic risk through several other 
ways. For example, thrombotic risk increases with the level of physical inactivity32 and 
physical inactivity is more common in subjects with high BMI.33,34 Another explanation 
for the relationship between BMI and VTE could be an increase in FVIII level. This 
protrombotic factor is known to be elevated in subjects with high BMI35,36 and could play 
a role in the development of VTE. 
 We acknowledge that our study has limitations. First, incidence of VTE may have 
been underestimated as cases were identified retrospectively. Nonetheless, the assessor 
who investigated patient charts was blinded to insulin and glucose status and there is no 
reason to assume an unequal distribution of missed events between different levels of 
insulin resistance. Second, the cohort under investigation is enriched for participant with 
higher levels of albuminuria. This enrichment, however, is unlikely to have influenced 
our risk estimates (i.e. HRs), as these estimates did not significantly change after 
accounting for study design. Third, insulin and glucose levels, as well as the relevant 
covariates used in our analyses, were measured only once at inclusion. Changes in the 
values of these variables were not considered. In our opinion, this does not weaken our 
finding that insulin resistance is not related to VTE when controlling for BMI. Despite the 
time-lag between data assessment and VTE occurrence, both univariate and multivariable 
analyses showed the hypothesized association between insulin resistance and VTE. After 
adjustment for BMI, insulin resistance was no longer associated with VTE. As insulin 
resistance and BMI were strongly correlated, we feel that repeated measurements will 
not influence this confounding effect. Fourth, we did not have information on long-
term anticoagulant therapy for atrial fibrillation. Long-term anticoagulant therapy could 
influence VTE occurrence. However, as atrial fibrillation and insulin resistance are not 
related,37 there is no reason to assume an unequal distribution of subjects on long-term 
anticoagulant therapy due to atrial fibrillation between subjects with different levels of 
insulin resistance. Therefore, this is not likely to have influenced our results.
 Lastly, we investigated PAI-1 as pro-coagulant factor. Unfortunately, data on vWf 
and fibrinogen levels were not available, and we could therefore not adjust for these 
variables. Data on other acquired and inherited thrombophilia factors were not available 
either. However, these variables have no known relationship with insulin resistance, and 
are therefore not likely to be a source of confounding.
 Strengths of this study are that to our knowledge it is the first study assessing insulin 
resistance as a risk factor for VTE. Moreover, the PREVEND cohort is a large population-
based prospective cohort in which insulin resistance is assessed as both fasting insulin 
and HOMA-IR. For both variables similar results were obtained with respect to the 
association between insulin resistance and VTE, indicating that our findings are robust 
and likely to be true. Furthermore, detailed and accurate data on cardiovascular risk 
factors were available. This provided us with other measures of body density, namely 
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waist circumference and waist/height ratio, which strengthens our findings regarding the 
role of body density in the relationship between insulin resistance and VTE. Additionally, 
information on diabetes treatment was available which made it possible to exclude 
these subjects in our analysis.
 In conclusion, we have shown an increased risk of VTE in subjects with increasing 
insulin resistance, but not independently of BMI. Our results suggest that insulin 
resistance is not essential for the development of VTE in overweight or obese subjects. 
Future studies should focus on other pathways that could explain the high thrombotic 
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Abstract
Studies on the association between lipid profile and venous thromboembolism 
(VTE) are inconsistent. This could be caused by classical lipoproteins being inferior to 
apolipoproteins as markers for VTE risk. Therefore, we examined whether apolipoproteins 
are more strongly related to VTE than lipoproteins. For this analysis we used the PREVEND 
prospective community based observational cohort study. Levels of apolipoprotein A1 
(ApoA1), apolipoprotein B (ApoB), total cholesterol (TC), high-density lipoprotein (HDL), 
non-HDL, low-density lipoprotein (LDL), triglycerides (TG), lipoprotein(a), ApoB/ApoA1 
and TC/HDL ratio were assessed. Subjects with VTE were identified using databases 
of the national registries of hospital discharge diagnoses, death certificates, and the 
regional anticoagulation clinic. Out of 7627 subjects, 110 developed VTE during a median 
follow-up of 10.5 years. In both univariate and multivariable analyses no significant 
associations between apolipoproteins and overall VTE were observed. Of the classical 
lipoproteins, TC, non-HDL, LDL, TG, and TC/HDL ratio were significantly associated with 
overall VTE in univariate analysis. Significant associations were no longer present in 
multivariable analysis. TGL and LDL were significantly associated with unprovoked VTE 
in univariate analysis. After adjustment for age and sex this significance was lost. No 
significant associations between (apo-) lipoproteins and provoked VTE were found. We 
conclude that apolipoproteins are not better in predicting VTE risk than the classical 
lipoproteins. Our population-based cohort study does not show an association between 
both apolipoproteins and the classical lipoproteins and VTE risk. 
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Introduction
Growing evidence shows a relationship between arterial and venous thromboembolism 
(VTE).1 A possible explanation for this relationship is an overlap in risk factors, such as an 
abnormal lipid profile. Indeed, the Jupiter trial showed that the use of statins decreases 
the risk of VTE.2 Two prospective, observational studies also reported a decreased risk of 
VTE associated with the use of statins.3,4
 Studies on the association between lipid profile and VTE, however, are inconsistent.5–9 
These studies mainly focused on classical lipoproteins (i.e. total cholesterol [TC], 
low-density lipoprotein [LDL], high-density lipoprotein [HDL], triglycerides [TG] and 
lipoprotein (a) [lp(a)]).5,6,10 However, in arterial thromboembolism, apolipoproteins and 
their ratios are possibly stronger predictors for the risk of arterial thromboembolism 
than the classical lipoproteins.11–13 This may also apply to venous thromboembolism. 
Possibly, the inconsistent results on the association between lipid profile and VTE are 
caused by the use of inferior risk markers which could not optimally detect the effect of 
an abnormal lipid profile on VTE risk.
 For this reason, we examined whether apolipoproteins are more strongly related to 
VTE than lipoproteins in the large population-based cohort of the Prevention of REnal 
and Vascular ENd stage Disease (PREVEND) Study. 
Lipid levels and venous thromboembolism
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Materials and Methods
Study population and design
This study was conducted on participants in the PREVEND Study. Details of this study 
have been published previously14 and can be found at http://www.prevend.org. In 
1997-1998, all inhabitants of the city of Groningen, the Netherlands, aged 28 to 75 years 
(n = 85 421), were invited to participate in this prospective cohort study, which was 
designed to investigate the natural course of albuminuria and its relation to renal and 
cardiovascular disease. A total of 40 856 subjects (47.8%) responded. Individuals with 
insulin-dependent diabetes mellitus were excluded from the PREVEND Study since the 
link between cardiovascular or renal disease and microalbuminuria in this population 
is well established. As pregnancy may cause temporary microalbuminuria, pregnant 
women were excluded from the study too. After these exclusions, all subjects with a 
urinary albumin concentration of 10 mg/l or greater (n = 7768) were invited and 6000 
agreed to participate. A random control sample of 3394 subjects with a urinary albumin 
concentration of less than 10 mg/l was invited and 2592 subjects agreed to participate. 
Taken together, 8592 subjects took part in the baseline screening and constitute the 
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PREVEND cohort. For the present study, we excluded participants who were nonfasting 
at the time of first blood sampling (n = 428) and those who used lipid-lowering drugs 
according to either pharmacy or self-report (n = 537). This left us with 7627 patients for 
the present analysis. 
 All participants provided written informed consent. The PREVEND Study was 
approved by the local medical ethics committee and was conducted in accordance with 
the guidelines of the Declaration of Helsinki.
Measurements
Participants visited the outpatient research unit twice for baseline survey. All participants 
completed a questionnaire on demographics, cardiovascular disease history, smoking 
habits, alcohol consumption and medication use prior to their first visit. Height and 
weight were measured, an 8 hour-fasting blood sample was drawn and two 24-hour urine 
samples were collected. Body mass index (BMI) was calculated as weight (kg) divided by 
square of height (m2). During the first and second visit blood pressure was measured, 
in supine position for 10 minutes with an automatic device (Dinamap XL Model 9300, 
Johnson-Johnson Medical, Florida, USA). Blood pressure values are given as the mean 
of the last two recordings of both visits. Hypertension was defined as systolic blood 
pressure of at least 140 mmHg, diastolic blood pressure of at least 90 mmHg, or the 
pharmacy-confirmed use of antihypertensive drugs.15 Diabetes mellitus was diagnosed 
by fasting plasma glucose ≥ 7.0 mmol/l, according to 1997 American Diabetes Association 
criteria16 or pharmacy-confirmed use of oral glucose-lowering drugs. Self-reported data 
on medication use were confirmed using pharmacy-dispensing information from all 
community pharmacies in the city of Groningen; drug use was available and complete 
for 85% of PREVEND participants. High-sensitivity C-reactive protein (hsCRP) and urinary 
albumin concentration were determined by nephelometry (Dade Behring Diagnostic, 
Marburg, Germany). For urinary albumin excretion, the mean of the two samples was 
used for analysis. Estimated glomerular filtration rate (eGFR) was estimated using the 
Modification of Diet in Renal Disease study equation, taking into account sex, age, race, 
and serum creatinine level.17 Subjects were classified as smokers when they reported 
smoking cigarettes during the previous year.
(Apo-) lipoproteins
Serum samples for lipid and apolipoprotein measurements were stored at -80 0C  until 
analysis. TC was measured by dry chemistry (Eastman Kodak, Rochester, NY, USA), TG 
were measured enzymatically. HDL was measured using a homogeneous method (direct 
HDL, AEROSET System; Abbott Laboratories, Abbott Park, IL, USA).18 LDL was estimated 
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using the Friedewald formula.19 NonHDL was calculated as the difference between TC 
and HDL. Serum apolipoprotein A1 (apoA1), apolipoprotein B (apoB), and lp(a) were 
determined by nephelometry applying commercially available reagents for Dade Behring 
nephelometer systems (BN II; Dade Behring, Marburg, Germany).20
Definition of thrombotic events
The database of the regional anticoagulation clinic, which monitors the anticoagulant 
therapy of all inhabitants of the city of Groningen, was used to identify participants of 
the PREVEND study who developed VTE between study entry and January 1, 2009. As 
an additional confirmation, the database of the national registry of hospital discharge 
diagnoses (Prismant, Utrecht, The Netherlands) was searched. Fatal cases were identified 
with the use of the database of the national registry of death certificates (Central Bureau 
of Statistics, The Hague/Heerlen, The Netherlands). When available, data on subjects 
with VTE according to any of the abovementioned databases was confirmed by patients’ 
medical records (n = 89). This was carried out by an assessor blinded for the lipid profile of 
the subject under investigation. Only objectively verified symptomatic thromboembolic 
events were considered. Deep vein thrombosis had to be confirmed by compression 
ultrasound, and pulmonary embolism by ventilation/perfusion lung scanning, or by 
spiral computed tomography. When VTE had occurred at or within three months after 
exposure to an exogenous risk factor including surgery, trauma, immobilisation for more 
than seven days, pregnancy, puerperium, the use of oral contraceptives or hormonal 
replacement therapy, or malignancy, this event was classified as being provoked. VTE 
was classified as unprovoked when no such risk factor was present. 
Statistical analysis
To examine the association between (apo-) lipoproteins and their ratios and VTE risk we 
used a Cox proportional hazard model. The following variables were examined: ApoA1, 
ApoB, TC, HDL, non-HDL, LDL, TG, lp(a), ApoB/ApoA1 and TC/HDL ratio. As the hazard 
ratio (HR) did not gradually increase with increasing levels of the (apo-) lipoproteins, 
these variables could not cot be included as continues variables. Therefore, the risk of 
VTE was analysed according to the tertiles of the (apo-) lipoproteins. Adjustments were 
made for age, sex, hypertension, diabetes, urinary albumin excretion, hsCRP and BMI. 
In these analyses urinary albumin excretion and hsCRP were log transformed (loge) to 
approach a normal distribution. First order interactions between the (apo-) lipoproteins 
and the variables included in the model were calculated. The HRs are reported with 
95% confidence intervals (95% CI). Observation time started with study entry and 
ended at time of VTE, end of study (January 2009), death or moving out of the city. 
Lipid levels and venous thromboembolism
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Various subanalyses were performed. Firstly, subjects with provoked and unprovoked 
VTE were analysed separately. Secondly, a sensitivity analysis was performed, in which 
all analyses were repeated without excluding subjects that were originally excluded 
based on the use of lipid-lowering medication. Lastly, design-based sensitivity analyses 
were performed, using survey probability weights,21 to correct for the enrichment of the 
cohort for subjects with high levels of urinary albumin excretion.
 Categorical data are presented as counts and percentages. Continuous variables are 
presented as medians with interquartile ranges (IQR) when not normally distributed, and 
as mean with standard deviation (SD) when normally distributed. Statistical difference 
was tested with the Mann-Whitney U test, Student’s t-test and Chi2 test. A two-tailed 
P < 0.05 was considered statistically significant. Statistical analyses were performed 
using PASW version 18.0 (IBM SPSS, Chicago, IL, USA). 
Results
Study population
Baseline characteristics are shown in Table 1. Of the 7627 subjects 49% were male. Mean 
age at enrollment was 49 (SD, 13) years. In 1949 subjects follow-up ended prematurely 
at time of death (n = 531, 7%) or moving out of the city (n = 1418, 19%). During a median 
follow-up of 10.5 (IQR, 10.2-10.8) years, 110 subjects developed VTE at a mean age 
of 61 (SD, 13) years. Median time from study inclusion to VTE was 4.9 (1.9-7.6) years. 
The annual incidence of VTE was 0.15 (95% CI; 0.12-0.18) per 100 person years. In 61 
subjects VTE was secondary to an external risk factor, 44 events were unprovoked. In 
five events the presence or absence of an external risk factor could not be assessed from 
medical records. Compared to subjects without VTE, subjects who developed VTE had 
significantly higher TC, non-HDL, LDL, TG and TC/HDL ratio at baseline. They also had 
significantly higher BMI, hsCRP and urinary albumin excretion and lower HDL and eGFR. 
Furthermore, subjects with VTE were more often hypertensive and were older.
Risk of VTE according to (apo-) lipoproteins
Inclusion of time dependent covariates in the Cox proportional hazard model showed 
that the proportional hazards assumption was not violated. Furthermore, there were 
no relevant significant first order interactions between the (apo-) lipoproteins and 
the variables included in the models. Table 2 shows the results of the univariate and 
multivariable analyses of the apolipoproteins in relation to overall VTE. In both univariate 
and multivariable analyses no significant associations between apolipoproteins and VTE 
were observed. 
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VTE = venous thromboembolism, HDL = high-density lipoprotein, LDL = low-density lipoprotein, 
‘Apo’ = apolipoprotein, TC = total cholesterol, UAE = urinary albumin excretion, hsCRP = high-
sensitivity C-reactive protein, BMI = body mass index, eGFR = estimated glomerular filtration rate. 
Categorical data are presented as number (%), continuous variables are presented as medians (IQR) 













































































Table 1 Baseline Characteristics
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Table 3 shows the results of the univariate and multivariable analyses of the classical 
lipoproteins and their ratios in relation to overall VTE. In the univariate analyses, TC, non-
HDL, LDL, TG and TC/HDL ratio were significantly associated with overall VTE. However, 
after adjustment for age and sex, a significant association was no longer present in 
all these variables. This was also true after additional adjustment for hypertension, 
diabetes, urinary albumin excretion, hsCRP and BMI. 
 When analyses were confined to subjects with unprovoked VTE we observed a 
significant association with TGL and LDL in the univariate analysis. After adjustment 
for age and sex no significant associations between unprovoked VTE and any of the 
(apo-) lipoproteins or their ratios remained. When confined to subjects with provoked 
VTE no significant associations between any of the variables and VTE was found in both 
univariate and multivariable analyses. 
 When a sensitivity analysis was performed in which subjects on lipid-lowering drugs 
were not excluded from analyses, similar results were found. In the univariate analyses 
non-HDL, LDL, TG and TC/HDL ratio were related to VTE risk. After adjustment for age 
and sex no significant relationship between any of the variables and VTE was found.
 When the analyses were adjusted for the enrichment of the cohort with participants 
with higher urinary albumin levels, using survey probability weights,21 similar results 
were obtained. In the multivariable analyses no significant relationship between any of 
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Discussion
The present population-based cohort study did not show a stronger association with VTE 
for apolipoproteins than for classical lipoproteins. Both apo- and lipoproteins showed 
no association with VTE, neither did their ratios. When analysed separately for subjects 
with unprovoked or provoked VTE similar results were found. 
 An association between lipid levels and VTE risk was hypothesized based on the 
established relationship between cardiovascular disease and VTE.1,22–24 Possibly, the 
relationship between the two diseases can be explained by an overlap in risk factors, 
such as an abnormal lipid profile. The lipid profile is largely influenced by food intake,25 
and dietary patterns are strongly related to the risk of cardiovascular disease.26–28 Diet 
patterns might also be related to VTE risk.29 However, the present study showed that, 
like many cardiovascular risk factors,5,6 an altered lipid profile does not influence VTE 
risk. This might explain why the relationship between healthy diets and VTE risk was 
not always corroborated.28,30 As abnormal lipid levels do not seem to influence VTE risk, 
we can conclude that the association between cardiovascular disease and VTE is not 
explained by an abnormal lipid profile. 
 Previously, a case-control study of 49 male VTE patients and matched controls, aged 
< 55 years, showed that VTE risk was elevated in subjects with an elevated ApoB/ApoA1 
ratio. When analysed separately low ApoA1 was associated with increased VTE risk while 
high ApoB level was not.8 On the contrary, Everett et al. reported that high levels of both 
ApoA1 and ApoB100 were associated with an increased risk of unprovoked VTE in women 
on hormone therapy.7 In contrast to abovementioned studies, our study was performed 
in a population-based setting. This might explain the differences in outcome. Everett et 
al. also did not show a relationship between apolipoproteins and VTE in women who 
were not on hormone therapy.7 Our findings are in accordance with the findings of a 
large population based cohort study in which no association between ApoA1 and VTE 
risk could be demonstrated.31
 Although not confirmed in a meta-analysis,13 two large case-control studies suggest 
that apolipoproteins are better than the classical lipid biomarkers in predicting the risk 
for arterial cardiovascular disease.11,12 The pathophysiology behind this finding is not 
fully understood, but is partly explained by the fact that apolipoproteins better reflect 
an individual’s atherogenic potential.32 Atherogeneity will most likely not influence VTE 
risk, because atherosclerosis does not take place in the venous system. Still, statins 
reduce the risk of VTE.2–4 Possibly, lipid biomarkers have other characteristics that could 
influence venous haemostasis. Indeed, it has been demonstrated that an elevated LDL 
level accelerates activation of prothrombin, factor X and factor VII, while HDL enhances 
the protein C anticoagulant pathway and reduces thrombin generation.33 Furthermore, 
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a high level of TC enhances platelet thrombus formation.34 However, the present study 
did not show an association between the lipid biomarkers and VTE risk. This suggests 
that the prothrombotic effects of an abnormal lipid profile might be too mild to actually 
influence VTE risk or that these effects are counteracted by other mechanisms. The 
reported decreased risk of VTE due to statins2–4 is probably not caused by lowering 
lipid levels itself, but more likely through other properties of this medication. This 
theory is supported by the finding that of all lipid-lowering medication, only statins 
reduce the risk of VTE.35 Statins have several other mechanisms that could reduce VTE 
risk. For example it induces Kruppel-Like Factor 2 expression, which in turn promotes 
thrombomodulin expression on endothelial cells, thereby enhancing the activity of the 
protein C anticoagulant pathway.36 Furthermore, statins diminish levels of inflammatory 
markers37,38 and they reduce tissue factor expression and thrombin generation.39
 Our study has both strengths and limitations. Strength of the study is that all important 
lipid biomarkers and the ratios known to be related to arterial cardiovascular disease 
have been examined. Including all important lipid biomarkers and ratios strengthens the 
finding that an altered lipid profile does not influence VTE risk. Other strengths of our 
study are the large population-based cohort and the accurate information on the use of 
lipid-lowering medicine, which made it possible to exclude these subjects in our analysis.
 A limitation of our study is that incidence of VTE may have been underestimated 
as cases were identified retrospectively. Nonetheless, the assessor who evaluated 
patient charts was blinded to lipid profile and there is no reason to assume an unequal 
distribution of missed events between different levels of (apo-) lipoproteins. Second, data 
regarding anticoagulant therapy were only available for the subjects who developed VTE 
during follow-up. Hence, the use of anticoagulants was not included in our multivariable 
analyses. Third, the cohort under investigation is enriched for participants with higher 
levels of albuminuria. This enrichment might have reduced generalizability. However, it 
is unlikely to have influenced our risk estimates (i.e., HRs) on the relationship between 
(apo-) lipoproteins and VTE, as these estimates did not significantly change after 
accounting for study design. Generalizability might have also been slightly reduced due 
to the inclusion criteria of the PREVEND Study, in which inclusion was limited to subjects 
aged 28-75 years at baseline. This might explain the somewhat low mean age at time 
of VTE found in our study, when compared to other studies.40,41 Fourth, lipid profile was 
assessed at inclusion. It is possible that lipid profile has changed during follow-up due to 
the natural course of lipid biomarkers or lifestyle intervention.
 The present study is important in understanding the pathophysiology of VTE. Our 
results show no association between either apolipoproteins or the classical lipoproteins 
and VTE risk. Apparently, the reported association between arterial cardiovascular 
disease and VTE is not explained by an altered lipid profile as shared risk factor. Future 
studies should focus on other mechanisms that can explain the association between 
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5 Elevated albuminuria associated with increased risk of recurrent venous thromboembolism: results of a population-based cohort study 
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This study examined the risk of recurrent venous thromboembolism (VTE) in patients 
with elevated albuminuria. In 1997-1998, inhabitants of Groningen, the Netherlands, 
aged 28-75 years (n = 85 421), were invited to participate in the PREVEND (Prevention of 
REnal and Vascular ENd stage Disease) Study, an observational, population-based cohort 
study. Albuminuria was measured and VTE occurrence was monitored in responding 
subjects (n = 40 856). Patients with first VTE between study entry and January 2009, 
identified through databases of the national registry of hospital discharge diagnoses, 
death certificates, regional anticoagulation clinic and medical records, were used for 
analysis. Of 351 subjects with first VTE, 37 subjects developed a recurrence during a 
median follow-up period of 3.3 (interquartile range, 1.1-6.4) years. Annual incidence of 
recurrence in subjects with elevated albuminuria (≥ 20 mg/l) was 5.00% [95% confidence 
interval (CI); 2.16-9.85], compared to 2.38% (95% CI; 1.59-3.41) in subjects with normal 
albuminuria (< 20 mg/l). Hazard ratio for recurrence was 1.95 (95% CI; 0.89-4.30) after 
adjustment for age and sex. This hazard ratio was 3.35 (95% CI; 1.18-9.47) in patients with 
first unprovoked, and 1.12 (95% CI; 0.25-5.01) in those with a first provoked event. This 
study showed that subjects with elevated albuminuria who experience an unprovoked 
VTE are at an increased risk of recurrence, independent of age and sex.  
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Introduction
Venous thromboembolism (VTE) is a major health problem in Western countries.1 
Reported incidence rates for first VTE vary between 1.4 and 1.9 per 1000 person-years.1–3 
Subjects with VTE are at high risk to develop recurrent VTE, with incidence rates reported 
as high as 26-95 per 1000 person-years.4–6 The risk of recurrence is especially high in 
subjects with first unprovoked VTE. These subjects have an almost twofold higher risk for 
recurrence than subjects with first provoked VTE.5 Prolongation of anticoagulation could 
reduce this risk, but must be balanced with the risk of bleeding.7–9 To optimize duration 
of anticoagulant therapy it is important to determine the risk of recurrence in subgroups 
of patients with VTE. 
 One of these subgroups could include subjects with an elevated urinary albumin 
concentration. Recently, we identified microalbuminuria as a risk indicator for first 
VTE.10 Subjects with microalbuminuria were at a 2.3-fold increased risk to develop 
VTE compared to subjects with albuminuria < 15 mg/24 h urine collection, whereas 
people with macroalbuminuria had a 3.0-fold increased risk compared to their healthy 
counterparts. Higher levels of albuminuria were particularly associated with unprovoked 
events. The increased risk of thromboembolism in patients with elevated albuminuria 
has been postulated to be associated with endothelial injury and/or the related changes 
in the levels of procoagulant proteins.10–13
 It is well recognized that many factors associated with an increased risk for first 
VTE are not related to a higher risk of recurrence.14 This seemingly paradoxical fact 
has recently been explained as index-event bias.15 However, there are no data on the 
influence of increased urinary albumin levels on recurrence of VTE. We therefore 
performed a population-based cohort study to determine whether subjects with 
elevated albuminuria have an increased risk of recurrent VTE.




This study was performed in participants of the Prevention of REnal and Vascular ENd stage 
Disease (PREVEND) Study. The PREVEND Study was designed to prospectively investigate 
the natural course of albuminuria and its relationship to renal and cardiovascular disease 
in a large cohort drawn from the general population. Details of this study have been 
published previously16 and can be found at http://www.prevend.org. In 1997-1998, all 
inhabitants of the city of Groningen, the Netherlands, aged 28-75 years (n = 85 421) 
were sent a postal questionnaire and a vial for them to collect an early morning urine 
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sample. Out of 40 856 responding subjects (47.8%), 597 subjects developed VTE during 
follow-up. After exclusion of subjects with a history of VTE (n = 104) and subjects who 
were using ongoing anticoagulant therapy from first VTE until end of study (n = 132), 351 
subjects with first VTE were eligible to participate, and used for analysis. Anticoagulant 
therapy was defined as therapeutic doses of vitamin K antagonists or low molecular 
weight heparin.
 The PREVEND study was approved by the local medical ethics committee and 
was conducted in accordance with the guidelines of the Declaration of Helsinki. All 
participants gave written informed consent.
Measurements
Urinary albumin concentration was established by a commercial immunoturbidimetry 
assay with sensitivity of 2.3 mg/l and inter- and intra-assay coefficients of variation of 
2.2 and 2.6%, respectively (BN II, Dade Behring Diagnostica, Marburg, Germany). First 
morning urine was used for analysis. Elevated albumin concentration was defined as 
≥ 20 mg/l, whereas a concentration of < 20 mg/l was defined as normal albuminuria.17
Definition of thrombotic events
Subjects with VTE between study entry and January 1, 2009 were identified using 
the databases of the national registry of hospital discharge diagnoses (Prismant, 
Utrecht, the Netherlands) and death certificates (Central Bureau of Statistics, The 
Hague/Heerlen, the Netherlands). Events and duration of anticoagulation were 
verified with the database of the regional anticoagulation clinic, which monitors the 
anticoagulant therapy of all inhabitants of the city of Groningen. When available, 
data on subjects with VTE according to any of the abovementioned databases was 
confirmed by accessing patients’ medical records (n = 332). This was carried out by an 
assessor blinded for albuminuria status of the subject under investigation. Deep vein 
thrombosis had to be confirmed by compression ultrasound, and pulmonary embolism 
by ventilation/perfusion lung scanning, spiral computed tomography, or at autopsy. VTE 
was classified as ‘provoked’ when it had occurred at or within 3 months after exposure 
to an exogenous risk factor including surgery, trauma, immobilization for more than 7 
days, pregnancy, puerperium, the use of oral contraceptives or hormonal replacement 
therapy, or malignancy. VTE was classified as ‘unprovoked’ when no such risk factor was 
present. Recurrence was established when demonstrated by objective techniques at 
another anatomical site than the first event, or at the same site, if previously repeated 
tests showed no residual venous thrombosis, or post thrombotic symptoms were not 
present before the second event.
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Statistical analysis
To determine whether elevated urinary albumin concentration increases the risk of 
recurrent VTE we estimated the absolute risk of recurrent VTE in subjects with normal 
albuminuria and in subjects with elevated albuminuria. The absolute risk was expressed 
as an annual incidence and was calculated by dividing the number of subjects with 
recurrent venous thrombosis by the total number of observation years. Observation time 
started after discontinuation of anticoagulant therapy and ended at time of recurrence, 
restart of long-term (> 3 months) anticoagulant treatment for another indication, end of 
study (January 2009), death or moving out of the city. The 95% confidence intervals (CIs) 
around the annual incidences were assessed with the Poisson distribution assumption. A 
Cox proportional hazard model was used to estimate whether increased albuminuria was 
a risk indicator for recurrent VTE. Adjustments were made for sex and age at time of first 
VTE. A test for the interaction of each variable with time showed that the proportional 
hazards assumption was not violated. Furthermore, there were no significant interactions 
between the variables included in the models, including albuminuria with type of index 
VTE (provoked vs unprovoked). Despite the absence of statistical heterogeneity we had, 
however, a priori planned a subgroup analysis in subjects with provoked and unprovoked 
VTE separately. The rationale for this analysis was the clinically relevant difference in 
the risk of recurrence in subjects with either a first unprovoked or a first provoked VTE.5 
 Given that the time between albumin measurement and VTE differed between 
subjects and often covered several years, it was possible that the risk for recurrent VTE, 
associated with an increased urinary albumin concentration, was attenuated. To explore 
this possibility we performed a sensitivity analysis in which the risk of recurrence in 
patients with elevated albuminuria was assessed after adjustment for time from albumin 
measurement to first VTE and its interaction with albumin concentration.
 To assess differences in duration of anticoagulant therapy between subjects with 
different levels of urinary albumin concentration a Mann-Whitney U test was performed.
 Categorical data are presented as counts and percentages, continuous variables as 
medians with interquartile ranges (IQR). Statistical significance was considered as a two-
tailed P <0.05. Statistical analyses were performed using PASW version 18.0 (IBM SPSS, 
Chicago, IL, USA) and SAS version 9.2 (SAS Institute, Inc., Cary, NC, USA). 
Albuminuria and recurrent venous thromboembolism
Results
Study population
Baseline characteristics are shown in Table 1. Of the 351 subjects, 49% were male. Median 
age at first VTE was 64 (IQR, 51-73) years. First VTE was secondary to an external risk 
factor in 170 subjects, and was unprovoked in 151 subjects. In 30 subjects the presence 
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or absence of an external risk factor could not be assessed from medical records. 
Median follow-up time was 3.3 (IQR, 1.1-6.4) years. Thirty-seven subjects developed a 
recurrent venous thrombosis at a median age of 69 (IQR, 59-74) years. Thirteen percent 
(n = 45) of the subjects had an urinary albumin concentration of ≥ 20 mg/l. Median time 
from albumin measurement to first venous thrombosis was 5.2 (IQR, 2.6-7.9) years, for 
recurrence this was 6.5 (IQR, 4.9-9.4) years. Median duration of treatment with vitamin 
K-antagonists did not differ between subjects with normal (< 20 mg/l) or elevated levels 
(≥ 20 mg/l) of albuminuria (6.0 (IQR, 3.9-6.2) and 5.9 (IQR, 3.1-6.2) months, respectively. 
P = 0.62). A total of 72 subjects were censored at time of death (n = 54, 15%) or moving 
out of the city (n = 18, 5%).
VTE = venous thromboembolism, UAC = urinary albumin concentration. Continuous variables are 
presented as median (IQR), categorical variables as number (%)

































Table 1 Baseline Characteristics
Total cohort UAC ≥ 20 mg/lUAC < 20 mg/l
Anticoagulant therapy first event
Risk of recurrent VTE in subjects with increased urinary albumin concentrations
Figure 1 shows the risk of recurrence in patients with elevated albuminuria. The annual 
incidence of recurrence in subjects with elevated albuminuria was twice that of subjects 
with normal albuminuria, 5.00 (95% CI; 2.16-9.85) versus 2.38 (95% CI; 1.59-3.41) per 
100 person-years. After adjustment for age and sex the hazard ratio (HR) was 1.95 
(95% CI; 0.89-4.30; P = 0.10). 
 Although heterogeneity of the effect of elevated albuminuria was not statistically 
significant, the increased risk was mainly powered by the subjects with a first 
unprovoked event. In this subgroup, the annual incidence was three times as high in 
subjects with elevated albuminuria as in subjects with normal albuminuria, 8.82 (95% 
CI; 3.24-19.21) versus 2.93 (95% CI; 1.67-4.75) per 100 person-years. In subjects with 
first unprovoked VTE, the adjusted (for age and sex) HR of recurrence in subjects with 
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This population-based cohort study is the first to investigate the association between 
elevated levels of urinary albumin and risk of recurrent VTE. We observed an almost 
twofold increased risk of recurrent VTE in subjects with elevated albuminuria. Our 
planned subgroup analysis indicated a difference in this risk between subjects with 
first unprovoked and first provoked VTE. A 3.4-fold increased risk of recurrence was 
observed in subjects with elevated albuminuria who had an unprovoked first VTE. The 
annual incidence of recurrence in these subjects was as high as 8.8%. No relationship 
between albumin level and recurrence rate was found in subjects in whom first event 
was provoked. 
 The present study was based on our previous study in which we showed a 
significantly higher risk of first VTE in patients with micro- and macroalbuminuria.10 Like 
in the present study, this relationship was mainly seen in patients with an unprovoked 
event. As the prevalence of recurrence in a population-based cohort is much lower than 
the prevalence of first VTE, we used a slightly different study design to assess the risk 
on recurrence to capture more events. In our previous study a subset of the 40 856 
responders was used, consisting of 8574 subjects who were phenotyped in great detail.10 
In the present study all the 40 856 responders were observed for development of first VTE 
between study entry and January 2009. Those who developed first VTE were included in 
this study. Instead of 24-h urine measurement, spot urine measurements were available 
for these subjects, with corresponding cut-off values for clinical classification (elevated 
albuminuria defined as albuminuria > 30 mg/24h or > 20 mg/l, respectively).16 Our 
previous study showed that this difference in albuminuria assessment did not materially 
affect outcome regarding the association between albuminuria and VTE.10 Furthermore, 
24-h urine measurement and spot urine measurement showed good correlation 
(r = 0.77).
 Our study has both strengths and limitations. Its strengths are the large population-
based cohort and the prospective way in which the subjects were followed. Furthermore, 
we have detailed information on the presence of risk factors for first VTE in the large 
elevated albuminuria was 3.35 (95% CI; 1.18-9.47), as compared to subjects with 
normal urinary albumin levels (P = 0.02). In contrast, this adjusted HR was 1.12 (95% CI; 
0.25-5.01) in subjects with first provoked VTE (P = 0.89).  
 A sensitivity analysis was performed to investigate whether the time lag between 
albumin measurement and VTE could have caused attenuation of the risk for recurrent 
VTE. This analysis showed no significant interaction between time from albumin 
measurement to first VTE and albumin level for risk of recurrence (P = 0.31).
majority of subjects. This is important, as the unprovoked nature of the first event is the 
most important risk determinant for recurrence.5
 A limitation of our study is that albumin measurements did not take place at the 
moment of VTE. It is possible that albumin status changed during this time. However, 
if this kind of misclassification had occurred, it has biased us towards the null. Also, 
our sensitivity analysis showed no interaction effect between albumin level and time 
from measurement to first VTE on the risk of recurrence. This suggests that time of 
albumin measurement has no major influence on the predictive value of albumin level 
for recurrent VTE. Similar long-term prognostic value of urinary albumin excretion has 
been observed for arterial cardiovascular outcome.18 A second limitation is that the 
incidence of VTE in our cohort may be underestimated as VTE cases were identified 
retrospectively. However, the assessor who investigated patient charts was blinded to 
albuminuria status and there is no reason to assume an unequal distribution of missed 
events between the different subgroups of albumin level. Lastly, we only adjusted for age 
and sex as independent risk determinants for recurrence. We could not correct for other 
determinants (e.g. D-dimer level at the end of anticoagulant treatment, deficiencies of 
the natural anticoagulants antithrombin, protein C, protein S). However, these factors 
have no known relation with albuminuria, and are therefore not likely to be a source of 
confounding.
 The present study identified elevated albuminuria as a risk indicator not only for first 
VTE but also for recurrence. Given that elevated albuminuria can distinguish between 
subjects with low or high risk for recurrence in patients with first unprovoked VTE, we 
can identify a subgroup of patients that might benefit from long-term treatment with 
anticoagulant therapy. It should be noted though that, due to small numbers, CIs were 
large. Large studies are needed to give a more precise estimation of the magnitude of 
the increased risk of recurrence after unprovoked VTE.
 In conclusion, our population-based cohort study showed an increased risk of 
recurrent VTE in subjects with elevated albuminuria who developed a first unprovoked 
VTE. It remains to be examined whether this should influence treatment decisions.
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Introduction Whether high factor VIII and low free protein S levels are risk factors for 
arterial thrombosis is unclarified. 
Material and Methods In a post-hoc analysis of a single-centre retrospective family 
cohort, we determined if these two proteins could increase the risk of arterial thrombosis. 
In total, 1399 relatives were analyzed. 
Results Annual incidence in relatives with high factor VIII levels was 0.29% 
(95% CI, 0.22-0.38) compared to 0.13% (95% CI, 0.09-0.19) in relatives with normal 
factor VIII levels. In relatives with low free protein S levels, this risk was 0.26% 
(95% CI, 0.16-0.40), compared to 0.14% (95% CI, 0.10-0.20) in relatives with normal free 
protein S levels. Mean factor VIII levels adjusted for age and sex were 11 IU/dl, 18 IU/dl, and 
21 IU/dl higher in relatives with hypertension, diabetes mellitus, and obesity as compared 
to relatives without these arterial thrombotic risk factors. Moreover, a dose response 
relation between increasing factor VIII and body mass index was found. None of these 
associations were shown for free 
protein S. 
Conclusions High factor VIII and low free protein S levels seemed to be mild risk factors 
for arterial thrombosis. High factor VIII levels were particularly observed in relatives with 
traditional arterial thrombotic risk factors. Free protein S levels were not influenced by 




Arterial thrombosis in subjects with arterial thrombotic risk factors is probably mediated 
by the presence of a prothrombotic and/or inflammatory state.1-5 Factor VIII and free 
protein S levels are both part of the clotting cascade, but have been reported to be 
associated with an inflammatory state when levels are high (for factor VIII),6 or low (for 
free protein S).7 Both high factor VIII and low free protein S levels, however, are also 
partially genetically determined.8,9  A high level of factor VIII is a well known risk factor for 
venous thrombosis,10,11 and possibly for arterial thrombosis as well.11,12 Whether low free 
protein S levels are a risk factor for arterial thrombosis is uncertain.13 Most information 
on low free protein S levels to the risk of arterial thrombosis comes from case reports or 
small case series.14-16
 We hypothesize that both high factor VIII levels and low free protein S levels increase 
the risk of arterial thrombosis either through a genetic or acquired link. Presence of 
a genetic association is assumed when protein levels are not influenced by (acquired) 
traditional arterial thrombotic risk factors. To test this hypothesis, we performed a 
retrospective study in a large series of families with thrombophilic defects to assess 
the risk of arterial thrombosis for different high factor VIII levels and low free protein S 
levels. 




This is a post-hoc analysis of pooled data from individual subjects of four large 
retrospective family cohort studies with various thrombophilic index defects from which 
outcomes have recently been published.17,18 These studies were performed by three 
university medical centers (Groningen, Amsterdam and Maastricht). As no central lab 
was involved, we choose to include only the data obtained from subjects in our centre 
(Groningen) to exclude interlaboratory variability in the present study. All studies were 
performed at the same time and laboratory tests had not changed over time. The 
first study comprised first-degree relatives (i.e., offspring, siblings, and/or parents) of 
consecutive patients (probands) with documented venous thrombosis and established 
hereditary deficiencies of either antithrombin, protein C, or protein S. As the number of 
antithrombin deficient probands was small, second-degree relatives (i.e., grandparents 
and/or blood related uncles or aunts) with a deficient parent were also identified. They 
were enrolled between April 1999 and July 2004. The other three studies comprised 
first-degree relatives of consecutive patients with venous thrombosis or premature 
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atherosclerosis (< 50 years of age) and the presence of either the prothrombin G20210A 
mutation, high levels of factor VIII at repeated measurements, or hyperhomocysteinemia. 
Enrollment started in May 1998 and was completed in July 2004. Approval was obtained 
from the institutional review board of University Medical Centre Groningen.
Subjects
All relatives, identified by pedigree analysis, were 15 years of age or older and were contacted 
through the probands. Written informed consent was obtained from all participants in 
accordance with the Declaration of Helsinki. Physicians at our thrombosis outpatient clinic 
collected detailed information on previous episodes of arterial thrombosis, risk factors 
for atherosclerosis, and anticoagulant treatment by using a standardized questionnaire 
(similar for all four studies) and reviewing medical records. Clinical data were collected 
before laboratory testing. Relatives were tested for deficiencies of antithrombin, protein 
C and protein S, factor V Leiden, prothrombin G20210A, and high levels of factor VIII. In 
addition, levels of free protein S were measured in most relatives. Due to shortage of 
stored plasma, free protein S levels could not be measured for all relatives. Factor VIII:C 
levels were measured by one-stage clotting assays (Behring, Marburg, Germany) and were 
considered ‘high’ at levels above 150 IU/dl to enable a comparison of results between 
this study and previous studies of ours.11 Free protein S antigen levels were measured 
after precipitation of protein S complexed with C4b-binding protein with polyethylene 
glycol.19 Normal ranges protein S were determined in 393 healthy blood donors, who 
had no (family) history of venous or arterial thrombosis and were neither pregnant, 
nor had used oral contraceptives for at least 3 months.20 A free protein S level below 
65 IU/dL was considered ‘low’, corresponding with the lower limit of the normal range in 
healthy volunteers. The CV of the free protein S assay was < 5%. Other laboratory tests, 
definitions of abnormal results, and criteria for inheritance of natural anticoagulant 
deficiencies have been described in detail elsewhere.17,18 To avoid bias, all probands 
were excluded from the analyses. In addition, relatives with protein S deficiency type 
I were excluded from analysis when analyzing effects of free protein S. This was done 
as protein S deficiency is classified into protein S deficiency type I (recognized by 
decreased levels of both total and free protein S antigen levels) and type III (recognized 
by decreased free protein S and normal total protein S antigen levels).21 Protein S 
deficiency type II, a functional protein S deficiency with reduced APC cofactor activity 
but normal total and free PS antigen levels, could not be determined due to the absence 
of a functional protein S assay in our hospital. Results of hereditary protein S type I 
deficiency on the risk of arterial thrombosis in this cohort have already been published 
and were therefore not primarily studied in the present study.22 For similar reasons, we 
did not primarily study the effect of hereditary antithrombin or protein C deficiency, 
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and prothrombin G20210A on the risk of arterial thrombosis.22,23 The number of 
factor V Leiden carriers in this cohort was too small to provide accurate relative risk 
estimates. Other studies and meta-analyses already showed that the increase in risk for 
arterial thrombosis in factor V Leiden carriers is negligible.24 Although previous study 
questions of ours included whether low free protein S and high factor VIIII levels influence 
the risk of arterial thrombosis in thrombophilic families,11,13 these studies did not provide 
answers to our current hypothesis, that is, whether high factor VIII or low free protein S 
levels are risk factors for arterial thrombosis through an acquired or genetic link. 
Definitions
Coronary and peripheral arterial disease had to be symptomatic and angiographically 
proven, whereas myocardial infarction was diagnosed according to clinical, enzymatic 
and electrocardiographic criteria. Ischemic stroke was defined as the onset of rapidly 
developing symptoms and signs of loss of cerebral function, which lasted at least 
24 hours and had an apparent vascular cause, as demonstrated by CT or magnetic 
resonance imaging. If a cerebral event completely resolved within 24 hours without 
cerebral lesions at scanning, it was classified as transient ischemic attack (TIA). 
Known risk factors for arterial thrombosis were recorded and included: hypertension, 
hyperlipidemia, the presence of diabetes mellitus, smoking habits or obesity defined as 
body mass index (BMI) > 30 kg/m2.
Statistical analysis
We analyzed the absolute risk of first arterial thrombosis in relatives, comparing those 
who did or did not have high factor VIII levels or low free protein S levels, respectively. 
We performed a sensitivity analysis where myocardial infarction and ischemic stroke 
were analyzed separately. 
 As both factor VIII and free protein S levels are continuous variables, a dichotomous 
breakdown in the analysis may seem artificial. Therefore, we also analyzed factor VIII 
and free protein S as continuous variables. A further stratification into quartiles, to 
investigate whether there was a dose-response effect, was not feasible due to small 
numbers. Observation time was defined as the period from the age of 15 years until the 
first arterial thrombotic episode or until the end of study. The 95% confidence intervals 
(95% CIs) around the incidence rates were calculated under the Poisson distribution 
assumption. Relative risks were adjusted for age and sex with Cox regression. Our study 
cohort consisted of thrombophilic families and subjects were therefore prone to have 
multiple thrombophilic defects.24,25 To provide as homogenous risk estimates as possible 
we therefore adjusted for antithrombin, protein C or protein S type I deficiency, factor V 
Factor VIII, free protein S and arterial thromboembolism
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Leiden and prothrombin G20210A with stepwise Cox regression. To account for the non-
randomness of the relatives analyzed, relative risks were also adjusted for clustering of 
events within families by using random-effects Cox regression and the robust sandwich 
method in Stata. 
 Linear regression was used to determine the relationship between factor VIII levels 
and free protein S levels, respectively, combined with traditional arterial thrombotic risk 
factors. Adjustments were made for age and sex.
 A cumulative distribution curve is a graphical representation in which two continuous 
variables can be compared directly. They were constructed to visualize a possible 
relationship between factor VIII and BMI, and free protein S and BMI and the occurrence 
of arterial thrombosis. 
 Continuous variables were expressed as mean values and standard deviations, 
categorical data as counts and percentages. Differences between groups were evaluated 
by the Student’s t-test and by Fisher exact test for categorical variables. A 2-tailed P-value 
of less than 0.05 indicated statistical significance. The statistical software used was SPSS 
version 16.0 (SPSS, Chicago, Illinois, United States) and Stata version 10.1 (Stata Corp., 
College Station, Texas).
Results
Our study cohort comprised 2451 relatives aged 15 years or older, of 380 probands 
(Figure 1). Of relatives, 518 (21%) had died before the start of the study. Another 
465 relatives did not participate because of various reasons, including refusal, 
inability to give informed consent, or residence outside The Netherlands (exclusion 
rate 24%). Of 1468 relatives tested for thrombophilia, 1399 were analyzed on factor 
VIII (missing laboratory data, n = 69) and 1143 were analyzed on free protein S 
(94 relatives excluded with protein S type I deficiency and 231 relatives with missing 
laboratory data). Forty-six percent were male (Table 1). Mean age at enrollment was 
45 years. Mean observation period was 30 years. Arterial thrombotic events were 
documented in 86 relatives (6%) at a mean age of 57 years. In relatives with high 
factor VIII levels mean age of occurrence of arterial thrombosis was 60 years. Mean 
age of arterial thrombosis in relatives with low free protein S levels was 55 years. Mean 
factor VIII level was 146 IU/dl and mean free protein S level was 80 IU/dl. 
 Annual incidence of arterial thrombosis in relatives with high factor VIII levels 
was 0.29% (95% CI, 0.22-0.38) compared to 0.13% (95% CI, 0.09-0.19) in relatives 
with normal factor VIII levels [crude relative risk, 2.2 (95% CI, 1.4-3.4)] (Table 2). 
When end-point myocardial infarction was chosen, this crude relative risk was 3.6 
(95% CI, 1.6-8.0). For ischemic stroke, this crude relative risk was 2.0 (95% CI, 0.8-4.8). 
Probands (n = 380)
Relatives ≥ 15 yrs total (n = 2451)
Relatives eligible (n = 1933)
Relatives tested (n = 1468)
Relatives analysed for factor VIII (n = 1399)
Relatives analysed for free protein S (n = 1143)
Antithrombin deficiency (n = 12)
Protein C deficiency (n = 40)
Protein S type I deficiency (n = 39)
Protein S type III deficiency (n = 81)
Prothrombin G20210A (n = 40)
High Factor VII (n = 69)
Hyperhomocycteinemia (n = 99)
Deceased (n = 518)
Excluded (n = 465)
Missing data (n = 69)
Missing data (n = 325)
Figure 1 Flow diagram of the family cohort
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Adjusted for age, sex and clustering of events within families, relative risk of arterial 
thrombosis in relatives with high factor VIII levels as compared to relatives with 
normal factor VIII levels was 1.5 (95% CI, 0.9-2.5). Age was the main determinant in 
the model that influenced this adjusted risk. After traditional arterial thrombotic risk 
factors were added in this model, relative risk was 1.4 (95% CI, 0.8-2.3). In relatives 
with low free protein S levels, annual incidence of arterial thrombosis was 0.26% 
(95% CI, 0.16-0.40), compared to 0.14% (95% CI, 0.10-0.20) in relatives with normal free 
protein S levels, crude relative risk 1.8 (95% CI, 1.1-3.1). When end-point myocardial 
infarction was chosen, this crude relative risk was 1.7 (95% CI, 0.7-4.2). For ischemic 
stroke, this crude relative risk was 2.1 (95% CI, 0.8-5.7). Adjusted for age, sex and 
clustering of events within families, relative risk of arterial thrombosis in relatives with 
low free protein S levels as compared to relatives with normal free protein S levels was 
1.7 (95% CI, 1.1-3.1). After traditional arterial thrombotic risk factors were added in this 
model, relative risk was 1.7 (95% CI, 1.0-2.9). As oral contraceptives may increase factor VIII 
levels and decrease free protein S levels,26 we performed a sensitivity analysis excluding 
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Table 1 Characteristics of 1399 relatives of probands with a thrombophilic defect
* 94 relatives with protein S type I deficiency excluded, total tested relatives 1143 
Male, n (%)
Myocardial infarction, n (%)
Factor VIII, mean (SD)
Hypertension, n (%)
Arterial thrombosis, n (%)
Transient ischemic attack, n (%)
Free protein S*, mean (SD)
Diabetes mellitus, n (%)
Age at onset arterial thrombosis, mean (SD)
Peripheral arterial thrombotic event, n (%)
Free protein S < 65 IU/dl*, n (%)
Previous smokers, n (%)
Obesity (body mass index > 30 kg/m2), n (%)
Classification
Thrombophilia
Arterial thrombotic risk factors
Long-term vitamin K antagonists, n (%)
















Age at enrollment, mean (SD)
Ischemic stroke, n (%) 

























all women who used oral contraceptives at time of enrollment. This did not change 
outcomes. Adjustments for various thrombophilic defects by stepwise Cox regression 
did also not change outcomes. When factor VIII and free protein S were analyzed as 
continuous variables in a Cox proportional-hazards model, the adjusted (for age, sex 
and clustering of events within families) relative risk of arterial thrombosis was 1.003 
(95% CI, 0.999-1.007) for each increase of 1 IU/dl in the level of factor VIII and 0.989 
(95% CI, 0.978-0.998) for each increase of 1 IU/dl in the level of free protein S.
 Cumulative distribution functions of free protein S levels and increasing factor VIII 
levels were overlying (Figure 2). Hence, no relationship between decreasing free protein 
S levels and increasing factor VIII levels was observed. 
 Table 3 shows mean factor VIII levels in relatives with hypertension, hyperlipidemia, 
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diabetes mellitus, obesity or previous smokers. Relatives with one of these traditional 
arterial thrombotic risk factors had mean factor VIII levels that were 24 IU/dl, 
17 IU/dl, 31 IU/dl, 10 IU/dl and 26 IU/dl higher compared to relatives without exposure 
to these risk factors. After adjustment of age and sex, these levels were 11 IU/dl, 5 IU/dl, 
18 IU/dl, 1 IU/dl and 21 IU/dl higher and still statistically significant for hypertension, 
diabetes mellitus, and obesity. Mean free protein S levels were similar in relatives who 
were exposed and not exposed to traditional arterial thrombotic risk factors, possibly 
except for relatives with obesity, as obese relatives appeared to have higher free protein 
S levels than non-obese relatives. Because we had continuous data on BMI, we could 
make cumulative distribution functions of factor VIII levels and free protein S levels on 
BMI. As shown in Figure 3A, an increase in factor VIII was associated with higher BMI. 
No such relationship was observed for free protein S levels (Figure 3B) suggesting that 
the earlier found increase of free protein S levels in obese versus non-obese relatives is 
a result of chance and not a real association. 
 Relative risk, adjusted for age, sex and clustering of events within families, for 
arterial thrombosis in relatives with hypertension was 1.8 (95% CI, 1.2-2.9) compared 

























Figure 2 Cumulative distribution function of free protein S levels in relatives of probands  with a 
thrombophilic defect
Factor VIII > 95th percentile (> 252 IU/dl)
Factor VIII 75th-95th percentile (173-252 IU/dl)
Factor VIII 50th-75th percentile (137-172 IU/dl)
Factor VIII 25th-50th percentile (110-136 IU/dl)
Factor VIII ≤ 25th percentile (≤ 109 IU/dl)
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to relatives with normotension. This risk remained unchanged after further adjustment 
for factor VIII. Relative risk for arterial thrombosis in relatives with hyperlipidemia, 
diabetes mellitus, previous smokers and obese relatives were 2.8 (95% CI, 1.8-4.4),  1.2 
(95% CI, 0.6-2.5), 1.5 (95% CI, 1.0-2.2) and 1.5 (95% CI, 0.8-2.9) adjusted for age, sex and 
clustering of events within families and compared to relatives without the exposure. 
Additional adjustment for factor VIII did also not change these outcomes.
Figure 3 Cumulative distribution function of factor VIII levels (A) and free protein S levels  (B) in 
relaives of probands with a thrombophilic defect according to body mass index

























Free protein S < 5th percentile
Free protein S  5th-25th percentile
Free protein S  25th-50th percentile
Free protein S  50th-75th percentile
Free protein S ≥ 75th percentile

























Factor VIII > 95th percentile
Factor VIII 75th-95th percentile
Factor VIII 50th-75th percentile
Factor VIII 25th-50th percentile
Factor VIII ≤ 25th percentile
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Discussion
This retrospective family study showed an approximately two-fold increased risk of 
arterial thrombosis in relatives with high factor VIII levels or low free protein S levels. Age 
had a strong effect on this risk in relatives with high factor VIII levels as, after adjustment, 
the risk dropped to 1.5. The risk of arterial thrombosis in relatives with low free protein S 
remained, however, unchanged after adjustment for age. Furthermore, factor VIII levels 
were higher in relatives with traditional arterial thrombotic risk factors, whereas no such 
association was observed for free protein S levels. Somewhat surprisingly, we could 
not demonstrate that higher factor VIII levels were associated with lower free protein 
S levels. This correlation could be expected as both thrombophilic abnormalities are 
associated with chronic inflammation7,27 and chronic inflammation is considered to be a 
risk factor for arterial thrombosis.3,4,27 On the other hand, that this association was not 
shown could be a consequence of the family design of our study. Although genotype-
phenotype associations in relatives with low free protein S levels were not determined in 
this study, it is likely that a genetic factor is involved as free protein S levels and arterial 
thrombotic risk were not influenced by age, and no association between free protein S 
levels with traditional arterial risk factors was shown. In addition, mean free protein S 
levels in this study (80 IU/dl) showed a left shift compared with the normal population 
(mean 100 IU/dl) which is likely a result of including thrombophilic families.17 Accordingly, 
one might expect the presence of low free protein S levels in relatives of patients with 
arterial thrombosis who have a family history of venous thrombosis or premature 
atherosclerosis. However, it cannot be concluded from this study whether testing for 
free protein S is useful for primary or secondary prevention of arterial thrombosis.
 Several methodological aspects of our study warrant comment. First, because 
the study had a retrospective design, where traditional arterial thrombotic risk 
factors were self-reported and/or derived from medical records, it is possible that 
misclassification occurred. This might have led to slightly lower risks and differences 
conferred by traditional arterial thrombotic risk factors, but was probably reduced by 
using a standardized questionnaire. Second, height and weight were self-reported. As in 
general, subjects with underweight tend to overreport their body weight, while subjects 
with overweight tend to underreport their body weight,28 actual risks and differences 
could be somewhat higher than reported if this phenomenon occurred. Third, referral 
bias may have been introduced by the university hospital setting. However, this was 
probably reduced by testing consecutive patients with thrombosis. Fourth, absolute risk 
estimates for arterial thrombosis were low in our study cohort. This clearly is a result 
of enrolling young relatives in the study as mean age at enrollment was 45 years in 
our cohort. Although generalizibility of our results for this reason is hampered (but also 
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because of the family cohort design) a family study of young participants is probably 
ideal to determine whether genetic variants are involved for arterial thrombotic disease 
occurrence as increasing age is strongly associated with an increased risk of arterial 
thrombosis.25 Fifth, although we used a large study cohort and long follow-up period, 
we only observed a relative small number of arterial events (total n = 86) that resulted in 
relatively wide confidence intervals. Hence, our study results should be interpreted with 
caution. 
 Finally, in this retrospective study, factor VIII levels were influenced by age, diabetes 
mellitus, obesity and hypertension. Causal inference of high factor VIII levels on arterial 
thrombotic risk can therefore not be inferred. Nevertheless, it might be interesting 
for future studies to determine why factor VIII levels increase with age, hypertension, 
diabetes mellitus and obesity. Shear stress (for hypertension) or endothelial damage (for 
increasing age) might explain these findings, but these hypotheses have, as far as we 
know, not been studied yet in humans. Furthermore, ABO blood group plays a significant 
role on factor VIII levels. This topic could not be covered in our study, as blood group was 
not measured. 
 Although free protein S levels were stable over time, and were not influenced by 
traditional arterial thrombotic risk factors, which assumes that low free protein S levels 
are genetically determined, we cannot exclude the possibility that this is based on 
residual confounding. Whether low free protein S levels are genetically determined can 
only be inferred with certainty from genotype-phenotype studies. The present finding 
that low free protein S levels are associated with arterial thrombosis, and our similar 
finding in a previous study, but then on venous thrombotic risk, which was independent 
of traditional venous thrombotic risk factors,17 could provide rationale for future studies 
to perform such a genotype-phenotype study. 
 We did not use a normal range of free protein S that was stratified on sex and 
age, although it is known that this is lower in premenopausal women than in men.20 
However, adjustment for sex and age did not change our outcomes. Furthermore, oral 
contraceptive use and hormonal replacement therapy decrease free protein S levels26 
and are known risk factors for venous thrombosis as well.29 Therefore, we performed 
a sensitivity analysis excluding all women who used oral contraceptives at time of 
enrollment. This did not change outcomes. 
 In conclusion, both high factor VIII levels and low free protein S levels seemed to be 
mild risk factors for arterial thrombosis in thrombophilic families. High factor VIII levels 
were particularly observed in relatives with traditional arterial thrombotic risk factors. 
Hence, it is questionable whether  a high factor VIII level itself increases risk of arterial 
thrombosis, or if this risk is explained by other, factor VIII associated arterial thrombotic 
risk factors, such as increasing age or hypertension. Free protein S levels were not 
influenced by traditional arterial thrombotic risk factors, which assumes that low free 
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VTE and ATE are generally seen as two different diseases. In the past decade, however, 
this dichotomy has been questioned. Chapter 1 described the latest findings on this 
topic and presented the outline of this thesis. 
Chapter 2
In chapter 2 the postulated relationship between ATE and VTE was examined. In a 
population-based cohort of 40 856 subjects, subjects with previous VTE were at increased 
risk to develop ATE. The annual incidence of ATE after VTE was 2.03%, compared to 
0.87% in subjects without VTE. After adjustment for age, sex, cardiovascular risk factors 
and history of ATE, the relative risk was still 1.4-fold increased. The risk was highest 
during the first year after VTE, in which 3% of the subjects developed ATE. This incidence 
was two times higher than the incidence in subjects without prior VTE.  Subjects who 
developed VTE in the absence of exogenous risk factors (unprovoked VTE) had the 
highest risk for ATE. The annual incidence of ATE was 2.53% in these subjects, which was 
1.6 times higher than in subjects without prior VTE. Apparently, VTE is an important risk 
marker for subsequent ATE.
Chapter 3
Several risk factors for ATE have been investigated regarding their relationship with 
VTE, but only obesity has consistently been shown to be an independent risk factor for 
VTE. Little is known about what mediates the relationship between obesity and VTE. 
Obesity is associated with a combination of risk factors that influence the risk of ATE, 
such as hypertension, dyslipidemia, and systemic inflammation. Insulin resistance has 
been suggested as central factor underlying this multifaceted syndrome. Possibly, insulin 
resistance also influences the venous system. In chapter 3 the relationship between 
insulin resistance and VTE risk was described. In a population-based cohort of 7393 
subjects, higher levels of insulin resistance were indeed associated with a higher risk 
of VTE. This association remained significant after adjustment for age, sex, traditional 
cardiovascular risk factors, C-reactive protein, albuminuria, and plasminogen activator 
inhibitor-1. However, after additional adjustment for body mass index, insulin resistance 
was no longer associated with VTE risk, whereas body mass index itself appeared to be 
a strong risk predictor for VTE. Our results suggest that insulin resistance is not essential 





An altered lipid profile is a well-known risk factor for ATE. Studies on the association 
between lipid profile and venous thromboembolism (VTE) are inconsistent. This could 
be caused by classical lipoproteins being inferior to apolipoproteins as markers for VTE 
risk. In chapter 4 we examined whether apolipoproteins are more strongly related to 
VTE than the classical lipoproteins. In a cohort of 7627 subjects, both univariate and 
multivariable analyses showed no significant associations between apolipoproteins and 
VTE. Several classical lipoproteins were significantly associated with VTE in univariate 
analyses. However, for all lipid biomarkers, significance was lost in multivariable analyses. 
When separate analyses were performed for subjects with provoked or unprovoked VTE, 
multivariable analyses similarly did not reveal any significant associations. We conclude 
that neither apolipoproteins nor classical lipoproteins predict VTE risk. 
Chapter 5
In chapter 5 the risk of recurrent venous thromboembolism (VTE) in patients with 
elevated albuminuria was investigated. Elevated albuminuria is a well-known risk 
factor for ATE. Recently our research group also observed an increased risk for VTE 
in subjects with elevated levels of albuminuria. Whether urinary albumin level also 
influences the risk of recurrent VTE has not been previously investigated.  Out of the 
baseline population-based PREVEND cohort of 40 856 subjects, 351 developed first 
VTE in the study period and were included in the analysis. The annual incidence of 
recurrence in subjects with elevated albuminuria (≥ 20 mg/l) was 5.00%, compared to 
2.38% in subjects with normal albuminuria (< 20 mg/l). After adjustment for age and 
sex, subjects with elevated albuminuria were at an almost two-fold increased risk to 
develop recurrence when compared to subjects with normal albuminuria. When 
subdivided into subjects with first provoked or unprovoked VTE, it appears that this 
increased risk was mainly explained by an increased risk in subjects with unprovoked 
VTE. Subjects with an unprovoked first VTE and elevated albuminuria were at a 
3.4-fold increased risk to develop recurrence when compared to subjects with normal 
albuminuria. In subjects with first provoked VTE, urinary albumin level did not influence 
the risk of recurrence. In conclusion, urinary albumin level can distinguish between high 
or low risk for recurrence in subjects with first unprovoked VTE.
Chapter 6
A high factor VIII level and a low free protein S level are associated with an increased risk 
for VTE. It is not clear whether these variables also influence the risk of ATE. This issue was 
addressed in chapter 6. In a family cohort of 1468 subjects we observed that factor VIII 
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and free protein S levels were mildly associated with ATE risk. The annual incidence 
in relatives with elevated factor VIII levels was 0.29%, compared to 0.13% in relatives 
with normal factor VIII levels. In relatives with low free protein S levels, this risk was 
0.26%, compared to 0.14% in relatives with normal free protein S levels. Hypertension, 
diabetes mellitus and obesity were associated with high levels of factor VIII, whereas free 
protein S levels did not show an association with any of the arterial cardiovascular risk 
factors. We postulated that low free protein S levels were genetically determined. We 
conclude that both elevated factor VIII levels and low free protein S levels are mild risk 
factors for ATE. However, it is questionable whether a high factor VIII level by itself 
increases ATE risk, or whether this increased risk is rather caused by the presence of 
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Discussion and future perspectives
The association between arterial and venous thromboembolism
ATE and VTE were traditionally considered as two different diseases. In 2003, Prandoni 
et al. were the first to report data that questioned this idea.1 Their data showed a 
two-fold increased risk for the presence of atherosclerotic plaques in subjects with 
unprovoked deep vein thrombosis.1 As a result of this study, more studies followed 
that observed an increased risk of ATE after VTE.2–8 In the present thesis, this finding 
was confirmed. Especially subjects with unprovoked VTE were at an increased risk to 
develop ATE and the risk of ATE was highest within the first year following VTE. This early 
occurrence of cardiovascular disease was also observed in a large 20-year cohort study.9 
This observation is even more remarkable as subjects with VTE receive anticoagulant 
therapy for three to six months following their event. Besides it protective effect on VTE, 
anticoagulant therapy is also known to reduce the risk of ATE. A large meta-analysis of 
31 randomized trials showed that anticoagulant treatment of high or moderate intensity 
(international normalized ratio of 2.8-4.8 and 2-3, respectively) is effective in reducing 
the risk of myocardial infarction and ischemic stroke.10
 A possible explanation for the early occurrence of ATE might be a rebound effect on 
coagulant factors.11–13 In the early sixties an increased incidence of cardiovascular events 
was observed after cessation of oral anticoagulant therapy.14 This notion, however, was 
not corroborated by others15–17 and therefore remains controversial. In the PREVEND 
cohort, used for our study, the presence of a rebound effect is unlikely as, out of 45 
subjects that developed ATE subsequent to VTE, only one subject developed ATE within 
a month after cessation of anticoagulant therapy. 
 An alternative explanation for the high incidence of ATE in subjects with previous 
VTE might be hospitalization bias. Patients with VTE may be diagnosed more often with 
subsequent ATE due to the fact that they are being extensively monitored after the 
development of VTE. Nonetheless, hard end points, like myocardial infarction, ischemic 
stroke and cardiovascular death should not be sensitive to such a bias. Both this thesis 
and previous research showed that the incidence of ATE was also higher in subjects with 
previous VTE, when restricted to these hard end points.2,6,7 With this, the presence of 
a hospitalization bias, as explanation for the high incidence of ATE after VTE, becomes 
unlikely. 
 All studies regarding the relationship between ATE and VTE failed to take the use of 
anticoagulants into account.2–8  Therefore, we cannot address the role of anticoagulant 
therapy itself on ATE risk. Recently, however, it has been suggested that long-term 
(> 10 years) use of vitamin-K antagonists accelerates arterial calcification.18 Matrix 
gamma-carboxyglutamic acid (G1a) protein (MGP) is an important calcification inhibitor 
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and carboxylation of this protein is vitamin-K dependent. It is presumed that vitamin-K 
antagonists increase vascular calcification through inhibition of MGP.19–21 Although we 
cannot exclude the possibility of arterial calcification in subjects with VTE, most likely 
this will not explain the high risk of subsequent ATE, given that standard therapy for VTE 
is only three to six months. Furthermore, abovementioned study investigated the effect 
of vitamin-K antagonists on arterial calcification in subjects aged younger than 55 years. 
Both VTE and ATE, however, occur considerably more often in subjects with older age. In 
older subjects, results on the relationship between long-term anticoagulant treatment 
and vascular calcification are contradicting.19–22 Additionally, as mentioned before, 
vitamin-K antagonist appeared effective in ATE prevention, due to the anticoagulant 
effects of these drugs.10
 Given these considerations the most likely hypothesis for the high risk of ATE within 
the first year after VTE is that a joint mechanism relates the two diseases. The presence 
of underlying pathology affecting the venous system might also affect the arterial system. 
The high risk of ATE in subjects with an unprovoked venous event compared to those 
with a provoked event, found in both the present thesis and other studies,2,23 supports 
this idea.
Arterial thromboembolic risk factors and the risk of venous thromboembolism
Which underlying pathologic mechanism could relate the two diseases is not known. 
Possibly, VTE and ATE have common risk factors. Several previous studies investigated 
this possibility and examined the effect of numerous arterial cardiovascular risk factors 
on the risk of VTE. Only obesity has consistently been shown to be related to VTE risk.24–27 
Results on other classical ATE risk factors, like hypertension, dyslipidemia, smoking, and 
diabetes, are contradicting.24–26,28
 In the present thesis we aimed to further explore the overlap between ATE and VTE 
risk factors. Because obesity is the only arterial cardiovascular risk factor that also clearly 
increased the risk of VTE,25–27,29 we first investigated the relationship between insulin 
resistance and VTE. Insulin resistance plays a central role in the cardiovascular risk 
profile of obese subjects.30–32 Furthermore, insulin resistance is related to endothelial 
damage and an increase in several prothrombotic factors.33–39 Our study indeed showed 
that subjects with higher levels of insulin resistance were at increased risk for the 
development of VTE. This association remained significant after correction for several 
cardiovascular risk factors. However, significance was lost after correction for body 
mass index. It appeared that the level of insulin resistance was strongly associated with 
body mass index. These results suggest that insulin resistance does not explain the 
relationship between ATE and VTE. However, although high body mass index does not 
seem to increase VTE risk through insulin resistance, high body mass index itself was 
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indeed related to a higher VTE risk. There are several other ways in which high body 
mass index can influence the risk of VTE. For example, thrombotic risk rises with the 
level of physical inactivity40 and physical inactivity is more common in subjects with high 
body mass index.41,42 Another explanation for the association between body mass index 
and VTE could be an increase in factor VIII level. This prothrombotic factor is elevated in 
subjects with high body mass index43,44 and possibly enhances the development of VTE 
in these subjects. 
 We further explored the relationship between ATE and VTE by investigating the 
association between lipid profile and VTE. We examined whether apolipoproteins are 
better at predicting VTE risk than the classical lipoproteins, and observed that this was 
not the case. In fact, apolipoproteins showed no relationship with VTE risk at all, nor 
did the classical lipoproteins in our cohort. This finding is remarkable as an altered 
lipid profile is known to affect haemostasis. Elevated LDL level accelerates activation 
of prothrombin, factor X and factor VII, whereas HDL is known to enhance the protein 
C anticoagulant pathway and to reduce thrombin generation.45 Furthermore, a high 
level of total cholesterol enhances platelet thrombus formation.46 The absence of an 
association between lipid profile and VTE risk suggests that these prothrombotic 
effects are probably too mild to actually influence VTE risk or that these effects are 
counteracted by other mechanisms. Our findings suggest that the reduced risk of 
VTE in subjects using lipid-lowering drugs47–49 should be ascribed to other properties 
of this medication, and not to its influence on lipid levels. This theory is supported by 
the finding that statins are the only type of lipid-lowering drugs that reduce the risk of 
VTE.50 Statins have several other mechanisms that could inhibit thrombus formation. 
Firstly, statins induce Kruppel-Like Factor 2 expression. Overexpression of Kruppel-Like 
Factor 2 promotes thrombomodulin expression on endothelial cells, thereby enhancing 
the activity of the protein C anticoagulant pathway.51 Furthermore, it causes a decreased 
level of plasminogen activator inhibitor-1.52 Secondly, statins are associated with 
diminished levels of inflammatory markers53,54 and with reduced tissue factor expression 
and thrombin generation.55
 Next, we investigated the relationship between albuminuria and the risk of recurrent 
VTE. High levels of urinary albumin are associated with an increased risk for ATE56–59 and 
recently a relationship with VTE was also shown.60 The increased risk of thromboembolism 
in patients with elevated albuminuria is hypothesized to be associated with endothelial 
injury and/or the related changes in the levels of procoagulant proteins.60–63 As risk 
factors for first VTE do not always distinguish between people at lower or higher risk for 
recurrence, we investigated whether this was the case for albuminuria. It appeared that 
subjects with unprovoked first VTE and high urinary albumin levels were at increased risk 
to develop recurrent VTE when compared to subjects with normal albuminuria.  These 
findings enable us to distinguish between people at high and low risk for recurrence. 
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This is important for the clinical management of VTE patients as it brings us closer 
to optimizing the balance between thrombotic and hemorrhagic risk. Furthermore, 
elevated albuminuria can be treated with other (non-anticoagulant) medicines, such 
as angiotensin converting enzyme inhibitors or angiotensin receptor blockers. Possibly, 
these medicines could also play a role in the treatment or prophylaxis strategies for VTE. 
This would be an interesting hypothesis to test. 
Venous thromboembolic risk factors and the risk of arterial thromboembolism
In addition to examining whether arterial cardiovascular risk factors predispose to 
VTE, the relationship between VTE risk factors and ATE incidence might also be useful 
in explaining the association between the two diseases. Indeed, VTE risk factors like 
pregnancy and the use of oral contraceptives are related to an increased risk of ATE.64–66 
The same is true for thrombophilia. Although relative risks are small, elevated levels 
of factors VIII, IX, XI and fibrinogen are associated with an increased risk of ATE.67,68 
Furthermore, Factor V Leiden and the 20210A prothrombin mutation, both known to 
increase circulating thrombin generation, might slightly add to ATE risk.69–71 The same 
applies to protein C and protein S type I deficiency.72,73 
 High factor VIII and free protein S levels are known risk factors for VTE.74–76 We 
investigated whether these factors also influence ATE risk and whether this occurs 
through either a genetic or an acquired link. For this purpose, we used pooled data of 
four family cohorts. Analyses showed a mildly increased risk of ATE in subjects with high 
factor VIII or low free protein S levels. In the case of factor VIII, high levels were associated 
with the presence of several arterial thrombotic risk factors. Hence, it is questionable 
whether high factor VIII levels itself increases ATE risk, or whether this increased risk 
is explained by other, factor VIII related, arterial thrombotic risk factors. Free protein S 
levels were not associated with arterial thrombotic risk factors. As both free protein S 
levels and arterial thrombotic risk factors are linked to inflammation,77–82 concomitant 
occurrence, however, is likely when low free protein S levels are acquired. The absence 
of such a balance, especially in a family cohort, assumes a genetic link. Furthermore, the 
association between free protein S level and ATE is not materially affected by age, which 
supports the assumption of genetic involvement.
 Although free protein S level is related to both VTE and ATE, it is unlikely to entirely 
explain the association between the two diseases. First, its association with ATE is mild. 
Second, it is probably through a genetic link that free protein S levels influence ATE risk, 
and hereditary protein S deficiency is rare. Therefore, this will probably not explain the 
high ATE incidence in VTE subjects in the general population. 
 The study design used to examine the association between both factor VIII and free 
protein S levels and ATE was not optimal. Firstly, a retrospective study design was used and 
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factor VIII and free protein S measurements took place at end of study. As measurements 
took place after ATE occurrence we can not be sure that levels were the same at time of 
ATE. Of course this problem is relatively small when it concerns genetically influenced 
levels, but factor VIII and free protein S levels can also be influenced by environmental 
factors. Secondly, we used a family cohort of young participants. ATE incidence is low in 
young subjects as ATE incidence is strongly associated with increasing age. This design 
is likely to have reduced generalizability, however, a cohort as used for our analyses, 
is very helpful in identifying genetic defects. As well as ATE incidence, the prevalence 
of acquired risk factors for ATE also increases with age. Consequently, especially young 
subjects with ATE are useful to detect genetic influences. Of course, actual genotyping 
would solve this problem and would enable us to detect the effect of genetic defects in 
more generalizable cohorts, but this type of research is expensive and time-consuming. 
Hence, in the case of rare genetic defects, a study design like ours can be useful and can 
serve as first step in exploring a possible genetic association.
Conclusion and future perspective
From this thesis we can conclude that a relationship between VTE and ATE indeed exists. 
The early occurrence and high incidence of ATE after an unprovoked VTE both suggest 
that a joint mechanism underlies this relationship. Most likely, as both VTE and ATE are 
multicausal diseases, the relationship between the two is also explained by multiple 
factors. Data from this thesis suggests that insulin resistance and an altered lipid profile 
do not explain the association. However, the PREVEND Study has a limitation when 
trying to explain the association between ATE and VTE; some relevant variables, such 
as levels of insulin, glucose and apolipoproteins, were measured only once, at inclusion. 
Any changes in these variables could therefore not be accounted for when assessing the 
risk for either VTE or ATE. In the ideal situation assessments take place right before ATE 
or VTE occurrence in order to examine its influence on the event. To approach this ideal 
situation repeated measures are required. This would enable us to investigate not only 
the influence of abnormal levels, but also the influence of changes in levels. 
 A population-based cohort study, like the PREVEND Study, is perfectly valid to 
maintain the generalizability of study results. However, as VTE incidence is not extremely 
high, huge cohorts are needed in order to draw firm conclusions about the relationship 
between VTE and ATE. In illustration of this point; out of the 40 856 subjects that formed 
the baseline PREVEND Study cohort, only 45 subjects developed VTE and subsequent ATE 
in a follow-up period of approximately 11 years. Due to this small number of endpoints 
there are clear limits to the expansion of statistical models. To solve this problem even 
larger cohorts should be obtained, a task that requires enormous resources. A solution 
to this problem is to form a high risk population cohort, for example, a cohort with older 
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subjects, as age is known to strongly influence both VTE and ATE incidence. This way, 
a minimum number of participants and a maximum number of patients are included. 
However, although saving time and costs, a certain loss of generalizability will occur. 
Another method to increase power could be to pool data of several cohorts that used 
designs similar to that of the PREVEND Study.
 Probably, a better solution is the use of existing ongoing prospective cohort studies. 
An example of such a study is the Lifelines study83 which aspires to include 165 000 
subjects to investigate the influence of hereditary and acquired factors on healthy aging. 
Every five years, this study intends to test a set of variables which could be of interest in 
exploring the association between VTE and ATE. If it is possible to link this database to the 
databases of the anticoagulant clinics and pharmacies, this study could be very valuable 
in exploring the association between VTE and ATE, while costs and time-consumption 
are minimal. 
 Data from literature and the present thesis suggest that obesity, vascular injury 
and inflammation might be of particular interest to explore in such a study, with 
respect to the association between VTE and ATE.24,60,84–87 Especially the role of obesity 
might be intriguing as its prevalence increased exponentially in the past years. In 
2009, almost fifty percent of the adult Dutch population was overweight or obese 
(body mass index ≥ 25 kg/m2).88 Another reason why overweight might be of special 
interest is that it can be measured and remedied without medical interfering. 
 Our study investigating the association between insulin resistance and VTE showed 
that body mass index measured at baseline is associated with an increased risk of VTE 
approximately five years later. This finding seems to indicate that overweight subjects 
generally remain overweight. Treatment and prophylactic strategies on lifestyle 
intervention, including diet and physical exercise, are daunting, but might gain huge 
benefit in the prevention of VTE as well as ATE. 
 Also without knowing the exact mechanism, the high incidence of ATE after VTE 
sheds a new light on the treatment of subjects with VTE. It implicates that the care for 
patients with VTE should not only focus on the prevention of recurrent VTE but also on 
the prevention of ATE. Possibly, the traditional treatment with vitamin-K antagonists can 
be extended with other medication. With this purpose, it might be valuable to screen 
subjects with VTE on arterial cardiovascular risk factors and treat them accordingly. This 
might even kill two birds with one stone as certain prophylactic strategies for ATE also 
reduce the risk for VTE. Statins, for example, are prescribed to normalize an altered lipid 
profile, but treatment also appears effective in reducing VTE risk.47–49  Furthermore, it 
might be useful to extend the traditional anticoagulant treatment of VTE with acetyl 
salicylic acid, a drug that is widely used in the prevention of ATE. At this moment 
there is insufficient evidence to advise this combined antiplatelet and anticoagulant 
treatment strategy, however, two ongoing studies (Warfasa, agnellig@unipg.it and 
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Aspire, aspire@ctc.usyd) address this issue. Effects on arterial outcome are not available 
yet, but initial results show that aspirin reduces the risk of recurrence in subjects with 
unprovoked VTE without increasing the risk of bleeding, when given after a treatment 
period with anticoagulants.89
 In conclusion, we can now firmly conclude that subjects with VTE are at increased 
risk for ATE. It is yet to be discovered what explains this association. Future studies 
should focus on reducing ATE risk after prior VTE by trying to explain the association and 
by investigating extended treatment strategies.
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Hart- en vaatziekten zijn doodsoorzaak nummer één in de westerse wereld. Onder deze 
noemer vallen onder andere een hartinfarct, herseninfarct, diep veneuze trombose en 
longembolie. Een hogere leeftijd is de belangrijkste risicofactor voor hart- en vaatziekten. 
Aangezien wij steeds ouder worden zullen deze ziekten een steeds belangrijker rol gaan 
spelen. 
 Bij veel vormen van hart- en vaatziekten is er sprake van overmatige stolselvorming 
waardoor een bloedvat (gedeeltelijk) afgesloten raakt. Wanneer dit het geval is dan 
spreken we van trombose. Trombose kan plaatsvinden in de slagaders (arteriën), die 
zuurstofrijk bloed naar de organen vervoeren, of in de aders (venen), die het bloed weer 
terug vervoeren naar het hart. In het eerste geval spreken we van arteriële trombose, 
in het tweede geval van veneuze trombose. Een hartinfarct en herseninfarct zijn 
voorbeelden van arteriële trombose. Veel voorkomende vormen van veneuze trombose 
zijn diep veneuze trombose in het been of longembolie. 
 Decennialang werd verondersteld dat arteriële en veneuze trombose twee 
verschillende ziektebeelden waren. De reden hiervoor was dat de beide typen trombose 
erg van elkaar verschillen met betrekking tot de risicofactoren, de ontstaanswijze en de 
samenstelling van het stolsel. Bekende risicofactoren voor arteriële trombose zijn roken, 
hoge bloeddruk, verhoogd cholesterol en diabetes. Deze factoren veroorzaken een 
beschadigde vaatwand. In reactie hierop blijven bloedplaatjes aan de wand kleven, wat 
langzaam maar zeker zorgt voor afsluiting van de slagader. De arteriële trombus bestaat 
dan ook met name uit bloedplaatjes. Bekende risicofactoren voor veneuze trombose 
zijn operaties, zwangerschap, gebruik van de anticonceptiepil, kanker, immobilisatie en 
afwijkende stollingsfactoren. Deze factoren hebben niet zo zeer invloed op de vaatwand, 
maar beïnvloeden de samenstelling van het bloed en de stroming van het bloed. Een 
veneuze trombus vormt zich in korte tijd en bestaat vooral uit rode bloedcellen en 
fibrinedraden. 
De relatie tussen arteriële en veneuze trombose
In de afgelopen tien jaar is de oorspronkelijke tweedeling tussen arteriële en veneuze 
trombose in twijfel getrokken. Mogelijk zijn deze ziekten meer met elkaar verbonden dan 
wij altijd vermoedden. Dit vraagstuk werd in het huidige proefschrift nader onderzocht. 
Hierbij maakten wij gebruik van het grote populatie cohort van de PREVEND Studie. In 
1997 is deze studie opgezet om de relatie tussen nierfunctie en arteriële trombose te 
onderzoeken. Alle inwoners van Groningen tussen de 28 en 75 jaar werden uitgenodigd 




Ruim 40 000 mensen reageerden op deze uitnodiging en leverden een ingevulde 
vragenlijst en een urine monster in. Al deze mensen werden in de daaropvolgende jaren 
gevolgd en gecontroleerd op de ontwikkeling van arteriële trombose. In het kader van de 
huidige onderzoeksvragen zijn deze data gekoppeld aan de data van de trombosedienst, 
die de behandeling van veneuze trombose mede uitvoert. Met deze gegevens en de 
gegevens van de medische dossiers verzamelden wij van alle 40 000 deelnemers een 
compleet overzicht van alle nieuwe gevallen van arteriële en veneuze trombose vanaf 
1997 tot 2009.
 Deze gegevens hebben we gebruikt om te onderzoeken of de in eerdere studies 
gevonden relatie tussen arteriële en veneuze trombose ook aangetoond kon worden 
in ons grote populatiecohort. Inderdaad vonden we dat mensen met een veneuze 
trombose een verhoogd risico hadden op het ontwikkelen van een arteriële trombose 
in vergelijking tot de mensen die nooit veneuze trombose hadden gehad. Dit risico was 
voornamelijk hoog in het eerste jaar na veneuze trombose. Drie procent van de patiënten 
met veneuze trombose ontwikkelde een hartinfarct, herseninfarct of andere arteriële 
trombose in het daaropvolgende jaar. Dit percentage was twee keer zo hoog als dat 
van mensen zonder veneuze trombose. Patiënten die een spontane veneuze trombose 
hadden ontwikkeld, dus zonder een duidelijk aanwijsbare oorzaak, hadden het hoogste 
risico op arteriële trombose. 
 Deze bevindingen deden ons vermoeden dat er een onderliggende afwijking bestaat 
die zowel veneuze als arteriële trombose uitlokt. Mogelijk hebben beide ziekten toch 
gemeenschappelijke risicofactoren. Dit vraagstuk hebben we nader onderzocht. 
Insuline resistentie
Glucose is een belangrijk bron van energie voor ons lichaam. Het is echter van belang 
dat de glucosespiegels in het bloed constant blijven. Om deze reden wordt er razendsnel 
insuline aangemaakt wanneer we glucose binnen krijgen via onze voeding. Insuline 
houdt de glucosespiegels op peil door de opslag van glucose in spieren en lever te 
stimuleren en de afbraak van glycogeen tot glucose te remmen. Wanneer iemand 
insulineresistent is, reageert het lichaam niet goed op insuline waardoor de cellen niet 
optimaal functioneren en de glucosespiegel in eerste instantie niet voldoende daalt. Dit 
compenseert het lichaam door nog meer insuline aan te maken. Wanneer het lichaam 
deze verhoogde insulineproductie niet meer aan kan zal dit resulteren in een verhoogde 
glucosespiegel. Wanneer de glucosespiegel een bepaalde grens overschrijdt spreken 
we van suikerziekte (Diabetes Mellitus). Hoge insuline- en glucosespiegels zorgen voor 
beschadigingen aan de vaatwand. 
 Mensen met overgewicht hebben een verhoogd risico op het ontwikkelen van 
arteriële trombose. Vaak gaat overgewicht gepaard met een scala aan arteriële 
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risicofactoren, zoals een verhoogde bloeddruk, verhoogd cholesterol en verhoogde 
ontstekingsactiviteit. Insulineresistentie speelt een sleutelrol in dit arteriële risicoprofiel. 
 Overgewicht verhoogt ook het risico op veneuze trombose. Mogelijk is 
insulineresistentie dus ook gerelateerd aan een verhoogd risico op veneuze trombose. 
Van de ruim 40 000 PREVEND deelnemers zijn 8500 deelnemers nader onderzocht 
op een aantal belangrijke arteriële risicofactoren, waaronder insulineresistentie. In 
deze groep onderzochten wij of insulineresistentie het risico op veneuze trombose 
beïnvloedde. Het bleek dat een sterkere mate van insulineresistentie inderdaad een 
verhoogd risico op veneuze trombose met zich meebracht. Deze relatie bleek echter 
afhankelijk te zijn van overgewicht. In andere woorden, mensen die insulineresistent 
zijn, hebben vaak ook overgewicht en waarschijnlijk is dit overgewicht de reden van het 
verhoogde risico op trombose. Onze studie bevestigt dat overgewicht zelf onafhankelijk 
gerelateerd is aan een verhoogd risico op veneuze trombose. Onze resultaten suggereren 
dat insulineresistentie niet essentieel is voor de ontwikkeling van veneuze trombose in 
mensen met overgewicht.
(Apo-) lipoproteïnen
Cholesterol en triglyceriden, samen bekend als lipiden, hebben een belangrijke functie 
in de energievoorziening en in de synthese van celmembraan en hormonen. Afwijkende 
lipidespiegels kunnen echter zorgen voor verkalking van de slagaders en geven daarmee 
een verhoogd risico op arteriële trombose. Lipiden zijn niet oplosbaar in water en binden 
daarom aan apolipoproteïnen om getransporteerd te kunnen worden door het bloed. 
Apolipoproteïnen bevatten fosfolipiden die de oplosbaarheid verbeteren. Wanneer 
lipiden en apolipoproteïnen binden, vormen ze samen lipoproteïne. De belangrijkste 
lipoproteïnen zijn High-Density Lipoproteïne (HDL) en Low-Density Lipoproteïne (LDL). 
HDL onttrekt cholesterol aan de cellen en transporteert het terug naar de lever die zorgt 
voor de uitscheiding ervan. HDL verlaagt de cholesterolspiegel en hoge HDL-spiegels 
hebben daarom een beschermend effect op het risico op arteriële trombose. Alle andere 
lipoproteïnen, waarvan LDL de belangrijkste is, zijn atherogeen. Dat wil zeggen dat ze het 
risico op aderverkalking verhogen en daarmee het risico op arteriële trombose. Deze 
atherogene lipoproteïnen transporteren lipiden van de lever naar de organen.
 Recent is aangetoond dat lipidenverlagende middelen, de zogeheten statinen, het 
risico op veneuze trombose verlagen. De literatuur is echter inconsistent wat betreft 
het effect van een afwijkend lipidenprofiel op het risico van veneuze trombose. Waar 
sommige studies inderdaad een relatie aantonen, doen andere dat niet. Mogelijk komt 
dit omdat er vrijwel alleen onderzoek is gedaan naar de klassieke lipide biomarkers 
(o.a. HDL, LDL en totaal cholesterol). De klassieke lipide biomarkers zouden echter wel 




laten zien dat apolipoproteïnen betere voorspellers zijn als het om het voorspellen van 
arteriële trombose gaat. In de 8500 nader onderzochte deelnemers van de PREVEND 
Studie onderzochten wij of apolipoproteïnen ook voor veneuze trombose betere 
risicovoorspellers zijn dan de klassieke lipide biomarkers. Dit bleek niet het geval. Zowel 
apolipoproteïnen als de klassieke lipide biomarkers waren niet gerelateerd aan veneuze 
trombose. Het positieve effect op het risico op veneuze trombose als gevolg van het 
gebruik van statinen ligt dus waarschijnlijk niet aan het lipidenverlagende effect, maar 
aan andere eigenschappen van deze medicijnen. We kunnen uit deze studie concluderen 
dat abnormale lipidenspiegels de relatie tussen arteriële en veneuze trombose niet 
kunnen verklaren.
Albuminurie
In de nieren wordt het bloed gefilterd en urine gevormd. Hierbij wordt de doorgang 
geblokkeerd voor grote eiwitten zodat deze de bloedstroom niet kunnen verlaten. Eén 
van deze grote eiwitten is albumine. Gezonde mensen hebben nauwelijks albumine 
in hun urine. In sommige gevallen is de albuminespiegel in de urine (albuminurie) 
echter verhoogd. Dit kan duiden op algehele vaatwandschade in het lichaam. Doordat 
de vaatwand in de nieren beschadigd is, kan het eiwit albumine in de urine lekken. 
Aangezien verhoogde albuminurie een marker is voor vaatwandschade is het een goede 
voorspeller voor het risico op arteriële trombose. 
 Onze studiegroep heeft recentelijk laten zien dat een hoge albuminespiegel in de 
urine ook een risicomarker is voor een eerste veneuze trombose. Het is echter bekend dat 
risicofactoren of -markers voor een eerste veneuze trombose vaak niet onderscheidend 
zijn voor het risico op een tweede veneuze trombose. Of dat het geval is voor verhoogde 
albuminurie is onbekend. Deze informatie is echter wel van groot belang voor de 
behandeling van patiënten met een eerste veneuze trombose. Na een eerste veneuze 
trombose krijgen patiënten antistollingsmiddelen toegediend. Deze behandeling duurt 
standaard drie tot zes maanden. Wanneer het risico op een tweede trombose heel hoog 
is, wordt een langduriger behandeling overwogen. Echter, antistollingsmiddelen gaan 
de vorming van nieuwe stolsels tegen, maar verhogen hiermee tegelijkertijd het risico 
op bloedingen. Om deze reden moet er een goede afweging gemaakt worden welke 
patiënten baat hebben bij een langdurige behandeling en welke, met het oog op de 
bloedingsneiging, beter niet langdurig behandeld kunnen worden. Daarom is het van 
belang patiënten te identificeren met een hoog risico op een tweede veneuze trombose. 
 Van het PREVEND populatiecohort van ruim 40 000 mensen ontwikkelden 351 
mensen een eerste veneuze trombose tijdens de studieperiode. Deze mensen werden 
gevolgd op het ontwikkelen van een tweede veneuze trombose, wat bij 37 mensen werd 
vastgesteld. Onze studie heeft laten zien dat mensen met een spontane eerste veneuze 
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trombose, dus zonder bekende uitlokkende factor, een drie keer zo hoog risico hebben 
op het ontwikkelen van een tweede veneuze trombose wanneer hun albuminespiegel 
in de urine verhoogd is. Aangezien verhoogde albuminurie een marker is voor 
vaatwandschade zou dit kunnen betekenen dat vaatwandschade ook een rol speelt bij 
veneuze trombose, hetzij direct dan wel indirect door het lekken van eiwitten die de 
stolselvorming tegen gaan. Deze grote eiwitten verlaten het bloed normaal niet, maar 
als albumine in de urine terecht komt zou dit ook kunnen gelden voor andere eiwitten. 
Ook blijkt een verhoogde albuminurie gerelateerd aan hogere spiegels van eiwitten die 
de stolling juist bevorderen. Wat het precieze mechanisme is achter het verhoogde risico 
op een tweede veneuze trombose in mensen met een verhoogde albuminurie moet 
dus nog nader onderzocht worden, maar onze studie suggereert dat mensen met een 
spontane eerste veneuze trombose en verhoogde albuminurie mogelijk gebaat zijn bij 
een langdurige behandeling met antistollingsmiddelen.
Factor VIII en vrij proteïne S
De vorming van een (veneus) stolsel wordt gereguleerd door een groot aantal eiwitten 
die de stolling bevorderen of juist tegengaan. Factor VIII is een eiwit dat de stolling 
bevordert. Hoge spiegels van dit eiwit zijn dan ook gerelateerd aan een verhoogd 
risico op veneuze trombose. Proteïne S is een eiwit dat de vorming van een stolsel 
juist tegen gaat. Proteïne S bestaat in een vrije vorm en in een vorm waarin het 
gebonden is aan een ander eiwit. Alleen de vrije vorm speelt een rol in de remming 
van stolselvorming. Een lage vrij proteïne S-spiegel is geassocieerd met een verhoogd 
risico op veneuze trombose. De FVIII- en vrij proteïne S-spiegels zijn gedeeltelijk erfelijk 
bepaald en worden deels beïnvloed door ontsteking. Ontsteking speelt een belangrijke 
rol bij de ontwikkeling van arteriële trombose in mensen met arteriële risicofactoren. 
Dit zou kunnen betekenen dat hoge factor VIII-spiegels en lage vrij proteïne S-spiegels 
ook gerelateerd zijn aan een verhoogd risico op arteriële trombose. We hebben dit 
onderzocht in een groot familiecohort van vier gecombineerde studies. In deze studies 
zijn familieleden geïncludeerd van patiënten met veneuze trombose óf aderverkalking 
op jonge leeftijd, en daarnaast een afwijking in één van de stollingsfactoren. De 
inclusies vonden plaats tussen 1999 en 2004. Bij alle deelnemers werd een groot aantal 
stollingseiwitten gemeten. Van de ruim 1400 deelnemers werd onderzocht of ze in het 
verleden arteriële trombose hadden doorgemaakt en of er arteriële risicofactoren bij 
hen aanwezig waren. Met behulp van deze informatie onderzochten we of hoge factor 
VIII-spiegels en lage vrij proteïne S-spiegels gerelateerd waren aan een verhoogd risico 
op arteriële trombose. Ook onderzochten we of de afwijkende spiegels een associatie 
vertoonden met de aanwezigheid van arteriële risicofactoren. Was dit het geval dan 




de afwijkende stollingseiwitten en de arteriële risicofactoren, dan namen we aan dat 
de afwijkende spiegels niet door ontsteking werden veroorzaakt, maar door erfelijke 
factoren. 
 Ons onderzoek liet zien dat beide factoren inderdaad milde risicofactoren zijn voor 
arteriële trombose. Een hoge factor VIII-spiegel bleek echter ook gerelateerd te zijn aan 
de aanwezigheid van arteriële risicofactoren. Mogelijk verklaart dit de relatie tussen 
factor VIII en het verhoogde risico op arteriële trombose. Een lage vrij proteïne S-spiegel 
was niet gerelateerd aan de aanwezigheid van arteriële risicofactoren. Aangezien 
een lage vrij proteïne S-spiegel en arteriële risicofactoren beide gerelateerd zijn aan 
ontsteking is het waarschijnlijk dat deze gelijktijdig optreden wanneer de vrij proteïne 
S-spiegel laag is onder invloed van ontsteking. Aangezien dit niet het geval was in het 
onderzochte familiecohort veronderstellen wij dat de lage vrij proteïne S-spiegels in ons 
cohort erfelijk bepaald zijn.
Conclusie en toekomstperspectief
Uit dit proefschrift kunnen we concluderen dat de veronderstelde relatie tussen 
arteriële en veneuze trombose inderdaad bestaat. Het hoge risico op arteriële trombose 
na een spontane veneuze trombose en het feit dat dit risico met name hoog is vlak na 
de veneuze trombose lijken erop te wijzen dat de beide ziekten een gemeenschappelijk 
onderliggend mechanisme hebben. Onze studies suggereren dat insulineresistentie en 
een afwijkend lipiden profiel geen onderdeel uitmaken van dit gemeenschappelijke 
mechanisme. Een verlaagde vrij proteïne S-spiegel is wel gerelateerd aan zowel arteriële 
als veneuze trombose. Het is echter onwaarschijnlijk dat deze samenhang de relatie 
tussen de twee ziekten geheel verklaart. Ten eerste is er slechts een milde relatie tussen 
een verlaagde vrij proteïne S-spiegel en arteriële trombose. Ten tweede verloopt deze 
relatie waarschijnlijk via een genetische link en een erfelijk proteïne S tekort komt maar 
zelden voor. Dit zal de hoge incidentie van arteriële trombose in de algemene bevolking 
dus waarschijnlijk niet verklaren.
 De onderzoeken in het huidige proefschrift en overige literatuur laten zien dat 
overgewicht, vaatwandschade en ontsteking mogelijk wel een rol spelen in de relatie 
tussen arteriële en veneuze trombose. Vooral overgewicht is een interessante factor voor 
nader onderzoek, gezien de stijgende prevalentie hiervan. Bovendien is overgewicht vast 
te stellen en te verhelpen zonder medisch ingrijpen. 
 Ook al kunnen we het mechanisme achter de relatie tussen arteriële en veneuze 
trombose nog niet doorgronden, de hoge incidentie van arteriële trombose na veneuze 
trombose werpt wel een nieuw licht op de behandelstrategieën van patiënten met 
veneuze trombose. Deze relatie suggereert dat we ons bij patiënten met een eerste 
veneuze trombose niet alleen moeten focussen op het voorkomen van een tweede 
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veneuze trombose, maar ook op het voorkomen van arteriële trombose. Mogelijk moeten 
we de behandeling van mensen met veneuze trombose uitbreiden. Het zou bijvoorbeeld 
nuttig kunnen zijn om mensen na hun eerste veneuze trombose te screenen op hun 
arteriële risicoprofiel en ze te behandelen daar waar nodig. Aangezien de medicijnen 
voor sommige arteriële risicofactoren ook het risico op veneuze trombose verlagen, zou 
dit zelfs twee vliegen in één klap slaan. Niet alleen het risico op arteriële trombose daalt, 
maar ook het risico op een tweede veneuze trombose. 
 Daarnaast zou het ook nuttig kunnen zijn om de huidige behandeling van veneuze 
trombose te verlengen met acetylsalicylzuur, een medicijn dat gebruikt wordt voor de 
preventie van arteriële trombose. Op het moment is er nog onvoldoende literatuur om 
een dusdanige combinatietherapie te adviseren, maar er zijn twee grote studies bezig 
dit te onderzoeken. Tot op heden zijn er nog geen resultaten bekend over het effect 
een combinatietherapie op arteriële trombose, maar de eerste resultaten laten zien 
dat het verlengen van de therapie van een eerste spontane veneuze trombose met 
acetylsalicylzuur, het risico op een tweede veneuze trombose verlaagt, zonder het risico 
op bloedingen te verhogen.
 Concluderend kunnen we nu met absolute zekerheid zeggen dat arteriële en veneuze 
trombose gerelateerd zijn. Wat deze relatie verklaart moet nog nader onderzocht 
worden. Toekomstige studies zouden zich moeten richten op het reduceren van het 
risico van arteriële trombose bij mensen met een eerdere veneuze trombose. Dit kan 
bewerkstelligd worden door een verklaring te vinden voor de associatie tussen de beide 
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Velen hebben mij geholpen bij de totstandkoming van dit proefschrift. Sommigen 
verrijkten mijn onderzoek met hun intellectuele kennis, anderen boden een luisterend 
oor en weer anderen zorgden voor de essentiële afleiding en gezelligheid. Graag wil ik 
jullie voor deze bijdragen bedanken.
Allereerst wil ik Jan bedanken voor het vertrouwen dat hij me heeft gegund toen hij mij, 
met als Bewegingswetenschappen niet de meest voor de hand liggende achtergrond, 
aannam als promovendus bij de stolling. Jan liet me vrij om de dingen te doen zoals ik 
ze voor me zag en zolang ik dat goed deed, was hij een tevreden man. Hij interesseerde 
zich voor wat je deed op en naast het werk en met een goed gevoel voor humor zorgde 
hij voor een ontspannen werksfeer. Een betere baas om mijn werkende leven mee te 
beginnen had ik me niet kunnen wensen. 
Na het plotselinge overlijden van Jan heeft Hanneke zijn taak als promotor overgenomen. 
Geheel niet makkelijk, want Jan had heel wat promovendi onder zich en had vrijwel 
niks (zo niet, helemaal niks) gedocumenteerd. Een moeilijke taak dus, maar met verve 
uitgevoerd. Daarvan getuigt onder andere dit proefschrift. Hanneke, ondanks alle extra 
drukte nam de snelheid waarmee je op je mails reageerde geenszins af. Stuurde ik om 
18:00 uur een artikel op, dan kon ik om 23:00 uur weer een gecorrigeerde versie in m’n 
inbox verwachten. Een zeer gewaardeerde eigenschap! Met een kritische blik heb je al 
mijn artikelen bekeken en in rap tempo van nuttig commentaar voorzien.
Karina, halsoverkop keerde jij naar Nederland terug om de Stolling met je expertise te 
verrijken. Toen bleek dat een schip met 5 kapiteins niet vooruit te branden was, heb ook 
ik daar aanspraak op gedaan. Met jou als begeleider voer het schip de laatste anderhalf 
jaar weer met volle vaart vooruit. Met behulp van jouw adviezen, feedback en nuchtere 
blik hebben we een aantal mooie artikelen weten te publiceren.
Ron, als tweede copromotor heb je een grote bijdrage geleverd aan dit proefschrift. Niet 
alleen leverde je me een grote hoeveelheid data, ook leerde je me alle ins en outs van 
deze enorm grote en ingewikkelde PREVEND database. Ik kon aankloppen wanneer ik 
wilde en het eerste wat je me op het hart drukte, was dat mijn bezoekjes laagdrempelig 
moesten zijn. Dit kon ik erg waarderen. Daarnaast vanzelfsprekend ook mijn grote dank 




Graag wil ik de leden van de leescommissie, prof. dr. F.R. Rosendaal, prof. dr. H. ten 
Cate en prof. dr. B.H.R. Wolffenbuttel bedanken voor het lezen en goedkeuren van mijn 
proefschrift.
Ook mijn medeauteurs, dr. Stephan Bakker, dr. Friso Muntinghe, dr. Robin Dullaart en 
Margaretha Visser wil ik graag bedanken voor hun bijdrage aan mijn artikelen.
Ina, Tineke en Marian, secretaresses van de Stolling, naast het werk dat jullie me uit 
handen hebben genomen, wil ik jullie ook bedanken voor het enthousiasme elke keer 
wanneer ik mijn nieuwste aankopen bij jullie kwam showen. Gelukkig waren de kritieken 
altijd positief! Jullie zijn een leuk en gevarieerd groepje; Tineke recht door zee en 
slagvaardig, Marian een echte levensgenieter en Ina vrolijk en (soms iets te) goedlachs 
(een paar steekwoorden: wespensteek, opgezwollen gezicht, tranen over de wangen, 
rollend over de grond… Dat is nog een verbeterpunt). Geregeld ben ik bij jullie aan 
komen waaien wanneer ik in een schrijversblok zat, wanneer mijn hart gelucht moest 
worden of als ik toe was aan wat gezelligheid. Ik hoop dat m’n volgende werkplek net 
zo’n gezellig secretariaat heeft. Met een net zo goed gevulde snoeppot.
Ina, jij in het bijzonder hartelijk dank voor al het logistieke werk rondom mijn promotie.
Nic, bij jou heb ik heel wat uren aan je bureau doorgebracht. Allerlei computers en 
supersnelle systemen haalde je erbij om mijn ingewikkelde statistische vraagstukken 
te kunnen beantwoorden. En als ik vervolgens al weer vrolijk verder zat te typen op 
mijn kamertje, zat jij nog minstens 24 uur met de gebakken peren, omdat de volledige 
computercapaciteit ingenomen werd door mijn berekeningen. Bedankt voor deze 
opoffering. Ook wil ik je graag bedanken voor je hulp wanneer ik in totale statistische 
stress verkeerde en je mails begon te sturen met onderwerpen als ‘PANIEK!’ en ‘HELP!’ 
Problemen werden door jou rap de kop in gedrukt zodat de rust snel wederkeerde.
Khan, mijn steun en toeverlaat in onderzoeksland! Ik ken niemand die zo behulpzaam is 
als jij. Alles kan je te allen tijde bij je neerleggen en je bent bereid iedereen te helpen. 
Daarbij word je ook nog gesierd door een ernstige vorm van bescheidenheid, want 
wanneer ik je na een vragenvuur van een uur hartelijk bedank voor je hulp antwoord je 
standaard: ‘Ja… ik heb eigenlijk niks gedaan…’ Khan, je bent een bijzondere collega met 
een groot hart. Al moest ik je soms aan een interview onderwerpen om wat over je te 
weten te komen, ik vond het erg interessant en leuk om jou en jouw cultuur zo te leren 
kennen.
Marieke, met veel plezier heb ik m’n jaren bij de Stolling aan ‘t bureau tegenover jou 
doorgebracht. Samen deelden we kamers op congressen en hebben we heel wat lol 
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gehad! Naast veel gezelligheid bood je me ook steun. Wanneer ik zwaar in de stress 
was voor een praatje voor heel wat toehoorders, dan nodigde je me gewoon een 
nachtje uit in jouw super-de-luxe 4-persoons hotelkamer, zodat ik alle stressverhogende 
medepromovendi niet bij het ontbijt trof. Dat kon ik heel erg waarderen. Je bent een 
gedreven, betrouwbare en lieve collega met een goed luisterend oor!
Vladimir, je hebt me nogal wat restricties opgelegd op alles wat ik hier over je mag 
schrijven, dus helaas kan ik niet te veel uitweiden over waarom ik je zo waardeer. 
Laten we dus maar zeggen dat ik je waardeer omdat je bent zoals je bent. Je praat 
het liefst over alles waar vrijwel niemand iets over wil horen, maar gelukkig zijn jouw 
favoriete gespreksonderwerpen ook mijn favoriete gespreksonderwerpen, dus van onze 
maandagochtend-bijklets-sessies heb ik altijd erg genoten. Zelfs aan jouw wekelijkse 
doel om mij te laten gillen door het vertellen van onsmakelijke verhalen kijk ik met 
plezier terug. Daarnaast heb ik grote bewondering voor jouw omgang met kritiek. Een 
eigenschap waar ik zeker wat van kan leren.
Hilde en Sophie, jullie zijn met name belangrijk geweest bij de laatste loodjes. Alle MEGA 
belangrijke beslissingen die er gemaakt moesten worden -‘Mat of glanzende voorkant?’ 
’90 grams papier of 100 grams papier? Ja, ik weet wel dat je het verschil verder niet 
echt ziet, maar ja, het moet wel goed zijn.’ ‘Sophie, wat denk jij, moet dit misschien net 
ietsiepietsie roder zijn?’ ‘En moet dit stippellijntje misschien toch een doorgetrokken 
lijntje worden?’- werden met jullie hulp wat makkelijker.
Verder wil ik Hilde nog bedanken voor haar whizzkid-brein, waar ook ik van mee kon 
profiteren. Al vind ik mensen die zich verheugen op ‘lekker een hele week statistieken’ 
doorgaans een beetje eng, als ik een statistische mening nodig had, kon ik altijd even 
met je brainstormen. 
Margriet, allereerst bedankt voor de samenwerking met de trombosedienst. Met jouw 
hulp is de basis voor mijn onderzoek gelegd. Daarnaast veel dank voor de gezelligheid 
die je meebracht op de kamer. Je gezonde zelfspot, je gevoel voor humor en je verhalen 
over je wilde jeugd maakten je een zeer welkome aanvulling op onze kamer.
Graag wil ik Nakisha, Anja en Lies bedanken voor de gezelligheid op congressen, 
cursussen en in het UMCG, de verpleegkundigen voor het eerste jaar dat ik bij jullie 
op de kamer heb doorgebracht, de labmedewerkers voor de borreltjes en taartjes die 
we samen hebben genuttigd, Marjan voor het congresplezier en je vrolijke lach die 
hier altijd door de kamer schalde, Joop voor de bijzondere, maar gezellige gesprekken, 
Lucia voor de meidenavonden en galajurk-keur-sessies, René voor je gezelschap bij de 
huisbezoeken en natuurlijk ook bij de congressen, Min Ki omdat je me introduceerde bij 
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de Stolling, Willem voor het feit dat je me bij m’n nekvel greep en met beide benen op de 
grond zette toen de stollingswereld onder m’n voeten weg dreigde te glijden en Heleen 
voor de keren dat je wat extra leven in de brouwerij op onze kamer bracht.
Bird, Es, Renée, Wouter, Rik en Jan, mijn vaste pauze-matties! De kopjes koffie en 
thee, de meetingen @ DE hoek, de PUUR, de fontein, de kinderspeelhoek en ‘my 
place’, de ontspannen wandelingetjes langs de meerkoetjes die we jaren lang voor 
waterhoentjes hebben uitgescholden, ons speelkwartiertje bij de YALP, springend en 
dansend rekensommetjes oplossen op t speelplein van de plaatselijke basisschool, met 
snoepjes strooien op de faculteit… Ze behoren zeker tot de leukste momenten van mijn 
onderzoeksbestaan! Bedankt!
Huize Vlassie, en dan met name Essie 1 en Essie 2, waar ik toch het grootste deel van 
mijn promotietraject bij in huis heb gewoond. Vele malen is mij gevraagd waarom ik 
nog steeds in mijn studentenhuis woon en of ik niet een keer iets anders wil. Met volle 
overtuiging zeg ik altijd ‘NEE!’ Al maken jullie me geregeld ’s nachts wakker omdat jullie 
de sleutel voor de 300ste keer zijn kwijt geraakt, ik vind jullie cool, leuk en heel gezellig 
en heb het ontzettend naar m’n zin (gehad) bij jullie in huis! En bovendien, een zeer 
handige bijkomstigheid, die studenten van tegenwoordig hebben zeeën van tijd. Dus als 
ik weer eens wat laat van m’n werk kwam -‘Nee, half 7 haal ik wel, ik doe dan ook wel 
even boodschappen.’ ‘Ok, half 7 lukt toch niet. 7 uur dan, inclusief boodschappen.’ ‘Half 
8 ook goed? En kan jij misschien toch die boodschappen even doen?’ ‘Ok, 8 uur ben ik 
thuis, en dan heb ik ook hele erge honger, dus zullen we doen dat het eten dan al klaar 
is?’ - dan kon ik altijd op ze rekenen. Thanks babes, voor al die lekkere maaltijden waarbij 
ik zomaar aan kon schuiven!
Dit laatste is overigens een punt waarop ik alle mensen met wie ik de afgelopen vier jaar 
heb gegeten moet bedanken. Wanneer ik net in een positieve en productieve vibe zat 
wou ik die altijd graag ten volle benutten, want je weet tenslotte nooit wanneer die weer 
komt, en helaas is mijn vibe altijd het best gebleken aan het eind van de middag/begin 
van de avond. Vele malen heb ik mensen dus op me moeten laten wachten… of voor 
me moeten laten koken. Hierbij ook met name een chapeau voor Maike, die geregeld 
uitgehongerd op me heeft staan wachten en er daarbij ook nog eens, in 99% van de 
gevallen, in slaagde haar irritatie hierover te verbergen.
DE groep; Marleen, Linda, Ankie, Maike, Marije, Rob, Jan-Maarten, Joeri, Thomas, Joris 
en Sander, bedankt voor jullie ontzettend hechte vriendschap. Ik ben blij dat we elkaar 
nog steeds zo veel zien en samen zo veel leuke dingen doen. De raarste dingen maak ik 
met jullie mee en het repertoire van hilariteiten blijft zich maar uitbreiden. Bedankt dat 
150
ik met jullie heerlijk los kan gaan!
Thomas, jij in het bijzonder, bedankt voor het leveren van gtst-materiaal de afgelopen 
jaren. De hele afdeling heeft hier uitgebreid van genoten. ;)
BW-ers, vakantiechickies, jaarclub- en dispuutsgenootjes en alle andere niet tot een 
specifieke groep behorende vrienden en vriendinnen, bedankt voor de gezellige 
borreltjes, etentjes, vakanties en weekendjes weg. Ontspanning draagt net zoveel bij 
aan dit proefschrift als inspanning.
Teamies, bedankt dat ik de onderzoeksfrustraties er samen met jullie, op het veld, lekker 
uit kon slaan. Zo kon ik weer met hernieuwde energie verder.
Joris, many thanks voor alle hulp bij de lay-out van dit boekje. Het is heel mooi geworden 
en ik ben er heel blij mee. En blij met jou, want je hebt me bergen werk uit handen 
genomen. Om zo iets te maken voor de perfectionistische Inge is bepaald niet makkelijk, 
maar iets waar jij prima mee om kan gaan. Wanneer ik allerlei gestreste sms-jes stuurde 
of je hier en daar wel aan had gedacht, gevolgd door 10 mails met punten die je absoluut 
niet moest onderschatten wanneer je een proefschrift moest lay-outen, dan kreeg ik 
gewoon een sms-je terug met de tekst ‘Inge, ik druk elke maand een boekje. Het komt 
goed.’ En zo werd ik weer even op m’n plek gezet en gedwongen de controle wat te laten 
vieren. En goede les voor mij.
Slimme Jaap, jou wil ik ook bedanken, want aan de hand van het format van jouw eigen 
proefschrift, konden wij het mijne maken. Dat heeft heel veel tijd bespaard. En niet 
alleen bij de afronding van het proefschrift ben jij van nut geweest, want gedurende het 
hele traject kon ik jou met vragen bestoken wanneer ik dat wou. Naast Einstein ken ik 
niemand die zo intelligent is als jij, en ik vind het bewonderenswaardig hoe jij altijd voor 
je vrienden klaar staat om deze intelligentie met ze te delen.
Marije, bedankt voor het zijn van mijn paranimf. Bedankt voor het helpen organiseren, 
het nemen van alle beslissingen van levensbelang en het meedenken over hoe ik dingen 
het beste aan kon pakken. Heel fijn dat voor deze periode het ‘je moet leren je eigen 
keuzes te maken, dus ik zeg lekker niks’- embargo even opgeheven kon worden. ;) Mede 
dank zij jouw hulp gaan we er een mooie dag van maken en een heel mooi feestje (er 
vanuit gaande dat ik het vragenvuur overleef natuurlijk ;) )
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Lieve mama en papa, door jullie ben ik geworden wie ik ben. Van jullie heb ik geleerd 
nieuwsgierig te blijven naar het onbekende, door te zetten wanneer het even tegen zit 
en te streven naar perfectie. Alle drie even belangrijke eigenschappen bij het voltooien 
van dit proefschrift.
Martine, mijn allerliefste zus, de afgelopen vier jaar hebben we heel wat uren aan 
de telefoon doorgebracht. Kletsend over alles in ons leven, maar toch ook voor een 
groot deel over onze onderzoeken. Naast jou ken ik vrij weinig mensen die net zo 
enthousiast worden als ik van de mededeling ‘Jaaaa, ik heb een significante relatie 
gevonden!!’ Ook bespraken we urenlang onze frustraties wanneer we een oneindigheid 
naar het computerscherm hadden lopen staren zonder een intelligent idee te hebben 
gekregen, wanneer onze databases niet deden wat wij wilden of wanneer deadlines ons 
angstaanjagend in de ogen keken. Bedankt voor al je steun de afgelopen jaren en bij de 
laatste loodjes als mijn paranimf!
Lieke, jij bent gewoon heel leuk. En mijn allerliefste zusje. Qua onderzoek was je 
misschien niet degene waar ik het meest op terugviel, want al probeerden we het wel 
eens, meestal eindigde dit in een: ‘Ja, Inge, daar moet je misschien Martine maar even 
voor bellen.’ Maar indirect heb ook jij aan dit proefschrift bijgedragen. Onder andere 
door je relativerende blik, waardoor ik dingen weer in perspectief ging zien. Daarnaast 
zorgen je persoonlijkheid en humor altijd voor een lach op m’n gezicht. En zonder 
ontspanning ook geen inspanning, dus de uren dat jij onder dwang spelletjes met me 
hebt gespeeld mogen hier ook wel even geroemd worden.
Ik prijs mezelf heel gelukkig met twee van zulke lieve zusjes waarbij ik ALTIJD terecht kan!
Tot slot, iedereen bedankt die het heeft volgehouden tot hier door te lezen. :)
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